

**CUMULATIVE
SUPPLEMENT 10
JAN'97-OCT'97**

APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES**

1997

RM
301.45
.A66
1997
Oct 10
Suppl

SUBSCRIBE NOW!

Available in March 1998

New 18th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

**18TH EDITION
1998**

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

RM301.45 .A66 1997 Oct Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

Cumulative Supplement 10

OCTOBER 1997

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Court Order Affecting Uruguay Round Agreements Act-Extended Patents	iv
1.3 Applicant Name Changes	v
1.4 Acyclovir 200 mg Tablet-Reference Listed Drug	vii
1.5 Follitropin Alfa and Beta	viii
1.6 Availability of the Publication and Updating Procedures	viii
1.7 Report of Counts for the Prescription Drug Product List	ix
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	72
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	76
2.4 Orphan Product Designations and Approvals List	77
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	86
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Terms	87
B. Patent and Exclusivity Lists	90

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

**CUMULATIVE SUPPLEMENT 10
OCTOBER 1997**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in *Merck, et al. v. Kessler*, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

CIBA GEIGY CORP
(CIBA GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

CIBA GEIGY CORP PHARMACEUTICALS DIV
(CIBA GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA PHARMACEUTICAL CO
DIV CIBA GEIGY CORP
(CIBA)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA SELF MEDICATION INC
DIV CIBA GEIGY CORP
(CIBA)

NOVARTIS CONSUMER HEALTH INC
(NOVARTIS)

CIBA VISION CORP
(CIBA)

CIBA VISION CORPORATION A
NOVARTIS COMPANY
(CIBA)

CIBA VISION OPHTHALMICS
DIV CIBA VISION CORP
(CIBA)

CIBA VISION CORPORATION A
NOVARTIS COMPANY
(CIBA)

FERRING LABORATORIES INC
(FERRING)

FERRING PHARMACEUTICALS INC
(FERRING)

GEIGY PHARMACEUTICALS
DIV CIBA GEIGY CORP
(GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

LEMMON CO SUB TAG PHARMACEUTICAL INC
(LEMMON)

BIOCRAFT LABORATORIES INC
(BIOCRAFT)

THEN CHANGED TO
TEVA PHARMACEUTICALS USA
(TEVA)

REXAR PHARMACAL
(REXAR)

SHIRE RICHWOOD INC
(SHIRE RICHWOOD)

RICHWOOD PHARMACEUTICAL CO INC
(RICHWOOD PHARM)

SHIRE RICHWOOD INC
(SHIRE RICHWOOD)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

SANDOZ CONSUMER HEALTH
CARE GROUP DIV SANDOZ PHARMACEUTICALS
(SANDOZ)

NOVARTIS CONSUMER HEALTH INC
(NOVARTIS)

SANDOZ PHARMACEUTICALS
CORP DIV SANDOZ INC
(SANDOZ)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

SANDOZ RESEARCH INSTITUTE INC
(SANDOZ)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

SANOFI WINTHROP INC
(SANOFI WINTHROP)

SANOFI PHARMACEUTICAL INC
(SANOFI)

SURVIVAL TECHNOLOGY INC
(SURVIVAL TECH)

MERIDIAN MEDICAL TECHNOLOGIES INC
(MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acyclovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): <http://www.fda.gov/cder>. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1996*</u>	<u>MAR 1997</u>	<u>JUN 1997</u>	<u>SEP 1997</u>
DRUG PRODUCTS LISTED	9392	9493	9533	9501
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)	2388 (25.0%)	2420 (25.5%)
MULTISOURCE	6905 (73.5%)	6991 (73.7%)	7031 (73.8%)	6970 (73.3%)
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)	6626 (69.5%)	6587 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)	405 (4.3%)	383 (4.0%)
EXCEPTIONS	104 (1.1%)	115 (1.2%)	114 (1.2%)	111 (1.2%)
NEW MOLECULAR ENTITIES APPROVED	--	6	8	14
NUMBER OF APPLICANTS	650	662	682	701

¹ Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

PRESCRIPTION DRUG PRODUCT LIST

1

17TH EDITION
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'97 - OCT'97

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER

25MG

N20482 004
MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BUCET

MALLINCKRODT

650MG; 50MG

N88991 001
JUN 28, 1985

BUTALBITAL AND ACETAMINOPHEN

GRAHAM DM

650MG; 50MG

N88991 001
JUN 28, 1985

CONTEN

GRAHAM DM

650MG; 50MG

N89405 001
MAY 15, 1990

TENCON

MALLINCKRODT

650MG; 50MG

N89405 001
MAY 15, 1990

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL

ACETAMINOPHEN, CAFFEINE

325MG; 50MG; 40MG

N88743 001
JUL 18, 1985

AB 325MG; 50MG; 40MG

N88765 001
MAR 27, 1985

AB 325MG; 50MG; 40MG

N89023 001
JUN 19, 1985

AB 325MG; 50MG; 40MG

N89067 001
APR 19, 1985

AB 325MG; 50MG; 40MG

N89102 001
JUN 19, 1985

AB 325MG; 50MG; 40MG

325MG; 50MG; 40MG

325MG; 50MG; 40MG

325MG; 50MG; 40MG

325MG; 50MG; 40MG

325MG; 50MG; 40MG

325MG; 50MG; 40MG

N89102 001
JUN 19, 1985

FEMCET

MALLINCKRODT

325MG; 50MG; 40MG

N89102 001
JUN 19, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

TRIAD

MALLINCKRODT

325MG; 50MG; 40MG

N89023 001
JUN 19, 1985

TABLET; ORAL

REPAN

GRAHAM DM

325MG; 50MG; 40MG

N87804 001
JAN 24, 1985

AB MALLINCKRODT

325MG; 50MG; 40MG

N87804 001
JAN 24, 1985

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

356.4MG; 30MG; 16MG

N40109 001
AUG 26, 1997

AA MIKART

DHC PLUS

356.4MG; 30MG; 16MG

N88584 001
MAR 04, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

500MG; 5MG

N87336 001
JUL 08, 1982

AA * GRAHAM DM

500MG; 5MG

N88956 001
JUL 19, 1985

HYDROCET

GRAHAM DM

500MG; 5MG

N89006 001
AUG 09, 1985

AA MALLINCKRODT

500MG; 5MG

N89006 001
AUG 09, 1985

LORCET-HD

+ MALLINCKRODT

500MG; 5MG

N87336 001
JUL 08, 1982

ZYDONE

MALLINCKRODT

500MG; 5MG

N88956 001
JUL 19, 1985

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

GRAHAM DM

500MG; 5MG

N87722 001
JUL 09, 1982

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ BARR

AA 500MG; 5MG

AA 500MG; 5MG

AA 750MG; 7.5MG

AA 500MG; 5MG

AA 750MG; 7.5MG

AA 500MG; 10MG

AA 500MG; 2.5MG

AA 650MG; 7.5MG

AA 500MG; 10MG

HYDROCODONE BITARTRATE N/ ACETAMINOPHEN

AA 500MG; 5MG

AA 500MG; 10MG

AA 500MG; 5MG

AA 500MG; 10MG

AA 325MG; 5MG

NORCO

+ WATSON LABS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA 500MG; 5MG

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA 325MG; 5MG

N88577 001

DEC 21, 1984

N40149 001

JAN 27, 1997

N40149 002

JAN 27, 1997

N40236 001

SEP 25, 1997

N40236 002

SEP 25, 1997

N40210 001

AUG 13, 1997

N40144 002

APR 25, 1997

N40155 001

APR 14, 1997

N40148 002

FEB 14, 1997

N88577 001

DEC 21, 1984

N40100 001

JAN 26, 1996

N87722 001

JUL 09, 1982

N40100 001

JAN 26, 1996

N40099 001

JUN 25, 1997

N40148 001

FEB 14, 1997

N40234 001

OCT 30, 1997

N40171 001

OCT 30, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCOCET

AA + DUPOINT MERCK

AA + ENDO PHARMS

325MG; 5MG

325MG; 5MG

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB VINTAGE PHARMS

AB 650MG; 100MG

N74843 001

FEB 12, 1997

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB TARO

AB 125MG

AB 250MG

N40195 001

MAY 28, 1997

N40195 002

MAY 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP ABBOTT

AP EQ 500MG BASE/VIAL

AP SANOFI WINTHROP

AP EQ 500MG BASE/VIAL

N40108 001

OCT 30, 1995

N40108 001

OCT 30, 1995

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; AURICULAR (OTIC)

TRIDESILON

@ BAYER

2%; 0.05%

N17914 001

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER

2%; 0.05%

N17914 001

> ADD >
> ADD >

> ADD >
> ADD >

ACYCLOVIR

CAPSULE, ORAL

ACYCLOVIR

AESGEN

200MG

AB

> ADD >
> ADD >

APOTHECON

200MG

AB

ESI LEDERLE

200MG

AB

LEK PHARM

200MG

AB

LEMMON

200MG

AB

MYLAN

200MG

AB

NOVOPHARM

200MG

AB

PUREPAC PHARM

200MG

AB

ROXANE

200MG

AB

TEVA

200MG

AB

ZENITH GOLDLINE

200MG

AB

ZOVIRAX

200MG

AB

+ GLAXO WELLCOME

200MG

AB

SUSPENSION, ORAL

ACYCLOVIR

ALPHARMA

200MG/5ML

AB

ZOVIRAX

200MG/5ML

AB

+ GLAXO WELLCOME

TABLET, ORAL

ACYCLOVIR

APOTHECON

400MG

AB

> ADD >
> ADD >

ESI LEDERLE

800MG

AB

> ADD >
> ADD >

400MG

AB

800MG

AB

ACYCLOVIR

TABLET, ORAL

ACYCLOVIR

LEK PHARM

400MG

AB

AB

NOVOPHARM

400MG

AB

AB

+

AB

PUREPAC PHARM

400MG

AB

AB

ZENITH GOLDLINE

400MG

AB

AB

ZOVIRAX

GLAXO WELLCOME

400MG

AB

AB

+

AB

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

ABBOTT

EQ 500MG BASE/VIAL

AP

EQ 500MG BASE/VIAL

AP

EQ 1GM BASE/VIAL

AP

EQ 1GM BASE/VIAL

AP

EQ 500MG BASE/VIAL

AP

EQ 1GM BASE/VIAL

AP

EQ 500MG BASE/VIAL

AP

> ADD >
> ADD >
> ADD >
> ADD >

N74658 001

APR 22, 1997

N74658 002

APR 22, 1997

N74556 002

APR 22, 1997

N74556 003

APR 22, 1997

N74556 001

APR 22, 1997

N74870 001

JUN 05, 1997

N74870 002

JUN 05, 1997

N74836 001

APR 22, 1997

N74836 002

APR 22, 1997

N20089 001

APR 30, 1991

N20089 002

APR 30, 1991

N74663 001

APR 22, 1997

N74758 001

APR 22, 1997

N74663 002

APR 22, 1997

N74758 002

APR 22, 1997

N74596 002

APR 22, 1997

N74596 001

APR 22, 1997

N74913 001

OCT 15, 1997

N74913 002

OCT 15, 1997

AMIKACIN SULFATEINJECTABLE; INJECTIONAMIKACIN SULFATEAP ABBOTTEQ 250MG BASE/ML

N64098 001

JUN 26, 1995

APEQ 250MG BASE/ML

N64099 001

JUN 20, 1995

AP

ELKINS SINN

EQ 50MG BASE/ML

N63274 001

MAY 18, 1992

⑥

EQ 50MG BASE/ML

N63274 001

MAY 18, 1992

AP

SANOFI WINTHROP

EQ 250MG BASE/ML

N64098 001

JUN 26, 1995

APEQ 250MG BASE/ML

N64099 001

JUN 20, 1995

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC

CONTAINER

ABBOTT

EQ 500MG BASE/100ML

N64146 001

APR 02, 1997

AMINO ACIDSINJECTABLE; INJECTION

AMINOSYN II 5%

ABBOTT

5%

N19438 002

APR 03, 1986

⑥

5%

N19438 002

APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM

IN PLASTIC CONTAINER

ABBOTT

3.5%

N19438 002

APR 03, 1986

N19438 002

APR 03, 1986

N19438 002

APR 03, 1986

N19438 002

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/

CALCIUM IN PLASTIC CONTAINER

ABBOTT

4.25%; 36.8MG/100ML; 20GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19714 002

SEP 12, 1988

4.25%; 36.8MG/100ML; 20GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19714 002

SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/

CALCIUM IN PLASTIC CONTAINER

ABBOTT

4.25%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19714 004

SEP 12, 1988

4.25%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19714 004

SEP 12, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM

IN PLASTIC CONTAINER

ABBOTT

5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19683 004

NOV 07, 1988

5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19714 003

SEP 12, 1988

5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19683 004

NOV 07, 1988

5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML

N19714 003

SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%; 33MG/100ML; 10GM/100ML;
51MG/100ML; 261MG/100ML; 217MG/100ML;
112MG/100ML N20678 002
MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%; 33MG/100ML; 25GM/100ML;
51MG/100ML; 261MG/100ML; 217MG/100ML;
112MG/100ML N20678 005
MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%; 33MG/100ML; 5GM/100ML;
51MG/100ML; 261MG/100ML; 217MG/100ML;
112MG/100ML N20678 001
MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%; 33MG/100ML; 10GM/100ML;
51MG/100ML; 261MG/100ML; 297MG/100ML;
77MG/100ML N20678 009
MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%; 33MG/100ML; 20GM/100ML;
51MG/100ML; 261MG/100ML; 297MG/100ML;
77MG/100ML N20678 011
MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%; 33MG/100ML; 25GM/100ML;
51MG/100ML; 261MG/100ML; 297MG/100ML;
77MG/100ML N20678 012
MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%; 33MG/100ML; 5GM/100ML;
51MG/100ML; 261MG/100ML; 297MG/100ML;
77MG/100ML N20678 008
MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%; 33MG/100ML; 10GM/100ML; 51MG/100ML;
261MG/100ML; 340MG/100ML;
59MG/100ML N20678 016
MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%; 33MG/100ML; 15GM/100ML; 51MG/100ML;
261MG/100ML; 340MG/100ML;
59MG/100ML N20678 017
MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%; 33MG/100ML; 20GM/100ML; 51MG/100ML;
261MG/100ML; 340MG/100ML;
59MG/100ML N20678 018
MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%; 33MG/100ML; 25GM/100ML; 51MG/100ML;
261MG/100ML; 340MG/100ML;
59MG/100ML N20678 019
MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%; 33MG/100ML; 35GM/100ML; 51MG/100ML;
261MG/100ML; 340MG/100ML;
59MG/100ML N20678 021
MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT N19505 002
NOV 07, 1986

3.5%; 25GM/100ML N19713 006
SEP 09, 1988

@ 3.5%; 25GM/100ML N19505 002
NOV 07, 1986

@ 3.5%; 25GM/100ML N19713 006
SEP 09, 1988

AMINO ACIDS; DEXTROSEINJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
 ABBOTT N19506 001
 NOV 07, 1986
 3.5%; 5GM/100ML

@ N19713 002
 SEP 09, 1988
 3.5%; 5GM/100ML

@ N19506 001
 NOV 07, 1986
 3.5%; 5GM/100ML

@ N19713 002
 SEP 09, 1988
 3.5%; 5GM/100ML

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
 ABBOTT N19713 001
 SEP 09, 1988
 4.25%; 10GM/100ML

@ N19713 001
 SEP 09, 1988
 4.25%; 10GM/100ML

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
 ABBOTT N19713 004
 SEP 09, 1988
 4.25%; 20GM/100ML

@ N19713 004
 SEP 09, 1988
 4.25%; 20GM/100ML

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT N19504 002
 NOV 07, 1986
 4.25%; 25GM/100ML

@ N19713 005
 SEP 09, 1988
 4.25%; 25GM/100ML

@ N19504 002
 NOV 07, 1986
 4.25%; 25GM/100ML

@ N19713 005
 SEP 09, 1988
 4.25%; 25GM/100ML

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT N19713 003
 SEP 09, 1988
 5%; 25GM/100ML

@ N19713 003
 SEP 09, 1988
 5%; 25GM/100ML

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 002
 SEP 29, 1997
 2.75%; 10%

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 005
 SEP 29, 1997
 2.75%; 25GM/100ML

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 001
 SEP 29, 1997
 2.75%; 5GM/100ML

AMINO ACIDS; DEXTROSEINJECTABLE; INJECTION

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 008
 SEP 29, 1997
 4.25%; 10GM/100ML

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 010
 SEP 29, 1997
 4.25%; 20GM/100ML

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 011
 SEP 29, 1997
 4.25%; 25GM/100ML

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 007
 SEP 29, 1997
 4.25%; 5GM/100ML

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 014
 SEP 29, 1997
 5%; 10GM/100ML

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 015
 SEP 29, 1997
 5%; 15GM/100ML

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 016
 SEP 29, 1997
 5%; 20GM/100ML

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 017
 SEP 29, 1997
 5%; 25GM/100ML

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
 BAXTER HLTHCARE N20734 018
 SEP 29, 1997
 5%; 35GM/100ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE;
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM
CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN
DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT

4.25%; 10GM/100ML; 51MG/100ML;
176.5MG/100ML; 22.4MG/100ML;
104.5MG/100ML; 205MG/100ML N19712 002

SEP 08, 1988

4.25%; 10GM/100ML; 51MG/100ML;
176.5MG/100ML; 22.4MG/100ML;
104.5MG/100ML; 205MG/100ML N19712 002

SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT

3.5%; 5GM/100ML; 30MG/100ML;
97MG/100ML; 120MG/100ML;
49.3MG/100ML N19712 001

SEP 08, 1988

3.5%; 5GM/100ML; 30MG/100ML;
97MG/100ML; 120MG/100ML;
49.3MG/100ML N19712 001

SEP 08, 1988

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

* SEARLE

25MG/ML

N87243 001

MAY 24, 1982

N87243 001

MAY 24, 1982

25MG/ML

N87239 001

N87239 001

N87387 001

JUN 03, 1983

N87387 001

JUN 03, 1983

25MG/ML

100MG

N84674 001

TABLET; ORAL

AMINOPHYLLINE

HALSEY

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@ HALSEY

100MG

N84674 001

TABLET, EXTENDED RELEASE, ORAL

PHYLLOCONTIN

* PURDUE FREDERICK

225MG

225MG

N86760 001

N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

HALSEY

10MG

50MG

75MG

N85923 001

N85925 001

N85926 001

MAY 20, 1983

N85927 001

MAY 20, 1983

N85923 001

N85925 001

N85926 001

MAY 20, 1983

N85927 001

MAY 20, 1983

100MG

N40218 001

SEP 11, 1997

N40218 002

SEP 11, 1997

N40218 003

SEP 11, 1997

N40218 004

SEP 11, 1997

N40218 005

SEP 11, 1997

N40218 006

SEP 11, 1997

AMITRIPTYLINE HYDROCHLORIDE

VINTAGE PHARMS

10MG

25MG

50MG

75MG

100MG

150MG

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

ICN

ROCHE

EQ 12.5MG BASE; 5MG

EQ 12.5MG BASE; 5MG

N16949 001

N16949 001

AMPHOTERICIN B

INJECTABLE; INJECTION

AB AMPHOTERICIN B
SANOFI WINTHROP

50MG/VIAL

N64141 001
DEC 23, 1986

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME
+ FUJISAWA

50MG/VIAL

N50740 001
AUG 11, 1997

ointment, TOPICAL

FUNGIZONE
+ APOTHECON

3%
3%

N50313 001
N50313 001

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ ZENITH GOLDLINE

EQ 250MG BASE
EQ 500MG BASE
EQ 250MG BASE
EQ 500MG BASE

N60765 001
N60765 002
N60765 001
N60765 002

AB
AB

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

ROBERTS LABS

EQ 0.5MG BASE

N20333 001
MAR 14, 1997

EQ 1MG BASE

N20333 002
MAR 14, 1997

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

+ GENESIA

0.05MG/ML

N20420 001
SEP 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

+ WYETH AYERST

5,000 UNITS/0.5ML

N20227 002
MAY 23, 1997

+

10,000 UNITS/0.5ML

N20227 001
MAY 23, 1997

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

* SAVAGE LABS

650MG; 50MG

N88305 001
OCT 13, 1983

@

650MG; 50MG

N88305 001
OCT 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL COMPOUND

@ ZENITH GOLDLINE

325MG; 50MG; 40MG

N85441 002
OCT 31, 1984

AB ZENITH LABS

325MG; 50MG; 40MG

N85441 002
OCT 31, 1984

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ PAR PHARM

385MG; 30MG; 25MG

N71642 001
JUN 23, 1987

ORPHENGESIC FORTE

@ PAR PHARM

770MG; 60MG; 50MG

N71643 001
JUN 23, 1987

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

@ ZENITH GOLDLINE

389MG; 32.4MG; 65MG

N83077 002
DEC 07, 1984

AA ZENITH LABS

389MG; 32.4MG; 65MG

N83077 002
DEC 07, 1984

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODASY

HAUSEY

325MG; 4.5MG; 0.38MG

N87464 001

JUL 01, 1982

325MG; 4.5MG; 0.38MG

N87464 001

JUL 01, 1982

PERCODAN

AA * DUPONT MERCK

AA + ENDO PHARMS

AA * PERCODAN-DEMI

AA * DUPONT MERCK

AA + ENDO PHARMS

325MG; 4.5MG; 0.38MG

325MG; 4.5MG; 0.38MG

325MG; 2.25MG; 0.19MG

325MG; 2.25MG; 0.19MG

N07337 006

N07337 006

N07337 005

N07337 005

ATENOLOL

TABLET; ORAL

ATENOLOL

AB MUTUAL PHARM

AB SIDMAK LABS NJ

AB

AB

AB

AB

25MG

25MG

50MG

100MG

N74499 001

JUL 30, 1997

N74101 001

JUL 17, 1997

N74101 002

JUL 17, 1997

N74101 003

JUL 17, 1997

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB SIDMAK LABS NJ

AB

50MG; 25MG

100MG; 25MG

N74107 001

SEP 24, 1997

N74107 002

SEP 24, 1997

ATACURIUM BESYLATE

INJECTABLE; INJECTION

ATACURIUM BESYLATE

AB ABBOTT

AB BEDFORD

10MG/ML

10MG/ML

N74633 001

DEC 23, 1996

N74901 001

JUL 18, 1997

ATACURIUM BESYLATE

INJECTABLE; INJECTION

ATACURIUM BESYLATE

AP ESI LEDERLE

10MG/ML

N74824 001

SEP 30, 1997

AP FAULDING

10MG/ML

N74740 001

MAR 28, 1997

AP GENISA

10MG/ML

N74784 001

JUN 11, 1997

AP OHMEDA

10MG/ML

N74753 001

JAN 23, 1997

ATACURIUM BESYLATE PRESERVATIVE FREE

AP ABBOTT

10MG/ML

N74633 001

DEC 23, 1996

AP

10MG/ML

N74639 001

MAR 25, 1997

AP BEDFORD

10MG/ML

N74900 001

JUL 18, 1997

AP ESI LEDERLE

10MG/ML

N74825 001

SEP 30, 1997

AP FAULDING

10MG/ML

N74741 001

MAR 28, 1997

AP OHMEDA

10MG/ML

N74768 001

JAN 23, 1997

TRACRIUM

AP * GLAXO WELLCOME

10MG/ML

N18831 001

NOV 23, 1983

+

10MG/ML

N18831 002

JUN 20, 1985

TRACRIUM PRESERVATIVE FREE

AP * GLAXO WELLCOME

10MG/ML

N18831 001

NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA ROXANE

0.025MG; 2.5MG

0.025MG; 2.5MG

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA ICN

0.025MG; 2.5MG

0.025MG; 2.5MG

0.025MG; 2.5MG

0.025MG; 2.5MG

0.025MG; 2.5MG

0.025MG; 2.5MG

0.025MG; 2.5MG

0.025MG; 2.5MG

AA KV PHARM

AA ZENITH GOLDLINE

N86057 001

N86057 001

N87195 001

FEB 16, 1982

N87195 001

FEB 16, 1982

N85659 001

N85659 001

N86727 001

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL

EMETE-CON

+ ROERIG

®

EQ 100MG BASE
EQ 100MG BASEN16818 006
N16818 006BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

® ALPHARMA

EQ 0.05% BASE

N71085 001
FEB 03, 1987AB NMC

EQ 0.05% BASE

N71085 001
FEB 03, 1987BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE

FOUGERA

EQ 0.1% BASE

N18861 001
AUG 31, 1983AB +

EQ 0.1% BASE

N18861 001
AUG 31, 1983

VALISONE

+ SCHERING

®

EQ 0.1% BASE
EQ 0.01% BASE
EQ 0.01% BASE
EQ 0.01% BASE
EQ 0.1% BASEN16322 001
N16322 002
N16322 002
N16322 002
N16322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

FOUGERA

EQ 0.1% BASE

N18866 001
AUG 31, 1983AB +

EQ 0.1% BASE

N18866 001
AUG 31, 1983

VALISONE

+ SCHERING

®

EQ 0.1% BASE
EQ 0.1% BASEN16932 001
N16932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

FOUGERA

EQ 0.1% BASE

N18865 001
AUG 31, 1983AB +

EQ 0.1% BASE

N18865 001
AUG 31, 1983

VALISONE

+ SCHERING

®

EQ 0.1% BASE

N16740 001

BETAMETHASONE VALERATE

OINTMENT; TOPICAL

VALISONE

® SCHERING

EQ 0.1% BASE

N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

+ ALCON

EQ 0.25% BASE; 1.75%

N20619 001
APR 17, 1997BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

® ZENITH GOLDLINE

25MG

N84689 001
N84689 001

AA ZENITH LABS

25MG

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

AP + BRISTOL MYERS SQUIBB EQ 30 UNITS BASE/VIAL

N50443 002
SEP 07, 1995

BLEOMYCIN SULFATE

AP PHARMACIA AND UPJOHN EQ 30 UNITS BASE/VIAL

N64084 002
JUN 01, 1996

EQ 30 UNITS BASE/VIAL

N64084 002
JUN 01, 1996BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE 200MG/100ML

N19837 002
APR 12, 1989

AP + 400MG/100ML

N19837 001
APR 12, 1989

200MG/100ML

N19837 002
APR 12, 1989

400MG/100ML

N19837 001
APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN
+ ALLERGAN 0.5%

N20490 001
MAR 13, 1997

AP SANOFI WINTHROP 0.25MG/ML

N74332 001
OCT 31, 1994

BROMFENAC SODIUM

CAPSULE; ORAL
DURACT
+ WYETH AYERST EQ 25MG BASE

N20535 001
JUL 15, 1997

AP ABBOTT EQ 0.3MG BASE/ML
AP SANOFI WINTHROP EQ 0.3MG BASE/ML

N74137 001
JUN 03, 1996
N74137 001
JUN 03, 1996

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE
@ ZENITH GOLDLINE 4MG
@ ZENITH LABS 4MG

N84351 001
N84351 001

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN
+ GLAXO WELLCOME 100MG
+ 150MG

N20358 002
OCT 04, 1996
N20358 003
OCT 04, 1996

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT
+ ASTRA 0.05MG/INH

N20233 001
FEB 14, 1994
N20233 001
FEB 14, 1994

ZYBAN
GLAXO WELLCOME 100MG

N20711 002
MAY 14, 1997
N20711 003
MAY 14, 1997
N20711 002
MAY 14, 1997
N20711 003
MAY 14, 1997

POWDER, METERED; INHALATION
PULMICORT
+ ASTRA 0.16MG/INH

N20441 002
JUN 24, 1997
N20441 003
JUN 24, 1997

BUTABARBITAL SODIUM

TABLET; ORAL
SODIUM BUTABARBITAL
@ ZENITH GOLDLINE 15MG
@ 30MG
@ ZENITH LABS 15MG
@ 30MG

N83484 001
N84040 001
N83484 001
N84040 001

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE
ABBOTT 0.25MG/ML

N74160 001
OCT 30, 1997
N74332 001
OCT 31, 1994

0.25MG/ML
0.25MG/ML

> ADD > AP
> ADD > AP

CAPTOPRILTABLET; ORAL
CAPTOPRIL
ENDO LABSAB 100MGAB 100MGAB 12.5MGAB 25MGAB 50MGAB 100MGAB 12.5MGAB 25MGAB 50MGAB 100MGAB 12.5MGAB 25MGAB 50MGAB 100MGCARBAMAZEPINECAPSULE, EXTENDED RELEASE; ORAL
CARBATROL
+ SHIRE LABS
+
200MG
300MG

TABLET; ORAL

AB 200MGAB 200MGCARBAMAZEPINE

TABLET, CHEWABLE; ORAL

AB 100MGAB 100MGCARBIDOPA; LEVODOPA

TABLET; ORAL

AB 10MG; 100MGAB 25MG; 100MGAB 25MG; 250MGAB 10MG; 100MGAB 25MG; 100MGAB 25MG; 250MGCARISOPRODOLTABLET; ORAL
CARISOPRODOL
AMIDE PHARMAA 350MGAA 350MGCARVEDILOLTABLET; ORAL
COREG

SMITHKLINE BEECHAM 3.125MG

N74418 004
FEB 13, 1996N74418 004
FEB 13, 1996N74640 001
MAR 31, 1997N74640 002
MAR 31, 1997N74640 003
MAR 31, 1997N74640 004
MAR 31, 1997N74677 004
MAY 30, 1997N74677 002
MAY 30, 1997N74677 001
MAY 30, 1997N74677 003
MAY 30, 1997N74532 001
MAR 28, 1997N74532 002
MAR 28, 1997N74532 003
MAR 28, 1997N74532 004
MAR 28, 1997N20712 001
SEP 30, 1997N20712 002
SEP 30, 1997N70541 001
SEP 17, 1986N70541 001
SEP 17, 1986N73524 001
JUL 29, 1992
N73524 001
JUL 29, 1992N73618 001
AUG 28, 1992
N73589 001
AUG 28, 1992
N73607 001
AUG 28, 1992
N73618 001
AUG 28, 1992
N73589 001
AUG 28, 1992
N73607 001
AUG 28, 1992N40188 001
MAR 07, 1997
N40245 001
SEP 08, 1997N20297 004
MAY 29, 1997

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN
@ APOTHECONEQ 250MG BASEN62973 001
NOV 08, 1988EQ 500MG BASEN62974 001
NOV 23, 1988EQ 250MG BASEN62973 001
NOV 08, 1988EQ 500MG BASEN62974 001
NOV 23, 1988@ PUREPAC PHARMEQ 250MG BASEN62809 001
APR 22, 1987EQ 500MG BASEN62809 002
APR 22, 1987EQ 250MG BASEN62809 001
APR 22, 1987EQ 500MG BASEN62809 002
APR 22, 1987CEPHAPIRIN SODIUMINJECTABLE; INJECTION
CEPADYL
@ APOTHECONEQ 1GM BASE/VIALN62724 001
DEC 23, 1986EQ 2GM BASE/VIALN62724 002
DEC 23, 1986EQ 1GM BASE/VIALN62724 001
DEC 23, 1986EQ 2GM BASE/VIALN62724 002
DEC 23, 1986CEPHRADINECAPSULE; ORAL
CEPHRADINE
@ ZENITH GOLDLINE250MGN62762 001
MAR 06, 1987500MGN62762 002
MAR 06, 1987@ ZENITH LABS250MGN62762 001
MAR 06, 1987500MGN62762 002
MAR 06, 1987CERIVASTATIN SODIUMTABLET; ORAL
BAYCOL
@ BAYER

0.05MG

N20740 001
JUN 26, 1997

0.1MG

N20740 002
JUN 26, 1997

0.2MG

N20740 003
JUN 26, 1997

0.3MG

N20740 004
JUN 26, 1997CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
OPHTHOCORT
@ PARKE DAVIS

10MG/GM; 5MG/GM;

N50201 002

10,000 UNITS/GM

N50201 002

10MG/GM; 5MG/GM;

N50201 002

10,000 UNITS/GM

N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

@ PARKE DAVIS

EQ 150MG BASE/5ML

N62301 001

EQ 150MG BASE/5ML

N62301 001

CHLORDIAZEPOXIDETABLET; ORAL
LIBRITABS
@ ROCHE

5MG

N85482 001

10MG

N85481 001

25MG

N85488 001

5MG

N85482 001

10MG

N85481 001

25MG

N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL@ ZENITH GOLDLINE

5MG

N83741 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
@ ZENITH GOLDLINE

50MG

N87947 001
FEB 27, 1984

AB ZENITH LABS

25MG

N88164 001
JAN 09, 1984

AB ZENITH LABS

50MG

N87176 001
FEB 27, 1984

AB ZENITH LABS

50MG

N87947 001
FEB 27, 1984

AB ZENITH LABS

25MG

N87555 001

BX THALITONE
HORUS THERAP

25MG

N88051 001
NOV 12, 1982

BX MONARCH PHARMS

15MG

N19574 001
DEC 20, 1988

BX MONARCH PHARMS

25MG

N19574 002
FEB 12, 1992

BX MONARCH PHARMS

15MG

N19574 001
DEC 20, 1988

BX MONARCH PHARMS

25MG

N88051 001
NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
LEMMON

500MG

N89859 001
MAY 04, 1988

AA LEMMON

500MG

N89859 001
MAY 04, 1988

AA LEMMON

250MG

N11300 003
N11300 003

AA LEMMON

250MG

N11300 003
N11300 003

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE
BAKER NORTON

EQ 4GM RESIN/PACKET

N74771 001
JUL 09, 1997

EQ 4GM RESIN/SCOOPFUL

N74771 002
JUL 09, 1997

CICLOPIROX

GEL; TOPICAL
LOPROX
+ HOECHST MARION RSSL 0.77%

0.77%

N20519 001
JUL 21, 1997

CIMETIDINE

TABLET; ORAL
CIMETIDINE
ENDO LABS

200MG

N74281 001
MAY 17, 1994

300MG

N74281 002
MAY 17, 1994

400MG

N74281 003
MAY 17, 1994

800MG

N74329 001
MAY 17, 1994

200MG

N74281 001
MAY 17, 1994

300MG

N74281 002
MAY 17, 1994

400MG

N74281 003
MAY 17, 1994

800MG

N74329 001
MAY 17, 1994

200MG

N74365 001
FEB 28, 1995

300MG

N74365 002
FEB 28, 1995

400MG

N74365 003
FEB 28, 1995

800MG

N74365 004
FEB 28, 1995

200MG

N74568 001
FEB 27, 1997

300MG

N74568 002
FEB 27, 1997

400MG

N74568 003
FEB 27, 1997

800MG

N74566 001
FEB 27, 1997

200MG

N74365 001
FEB 28, 1995

300MG

N74365 002
FEB 28, 1995

CIMETIDINE

TABLET; ORAL

CIMETIDINE

TEVA

400MG

N74365 003

800MG

FEB 28, 1995

800MG

N74365 004

FEB 28, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

ABBOTT

EQ 300MG BASE/2ML

N74296 001

EQ 300MG BASE/2ML

MAR 28, 1997

EQ 300MG BASE/2ML

N74412 001

EQ 300MG BASE/2ML

MAR 28, 1997

EQ 300MG BASE/2ML

N74005 001

EQ 300MG BASE/2ML

AUG 31, 1994

EQ 300MG BASE/2ML

N74005 001

EQ 300MG BASE/2ML

AUG 31, 1994

EQ 300MG BASE/2ML

N74296 001

EQ 300MG BASE/2ML

MAR 28, 1997

EQ 300MG BASE/2ML

N74412 001

MAR 28, 1997

SOLUTION; ORAL

CIMETIDINE HCL

ENDO LABS

EQ 300MG BASE/5ML

N74251 001

EQ 300MG BASE/5ML

DEC 22, 1994

EQ 300MG BASE/5ML

N74251 001

EQ 300MG BASE/5ML

DEC 22, 1994

EQ 300MG BASE/5ML

N74664 001

EQ 300MG BASE/5ML

OCT 28, 1997

EQ 300MG BASE/5ML

N74757 001

EQ 300MG BASE/5ML

OCT 17, 1997

EQ 300MG BASE/5ML

N74553 001

EQ 300MG BASE/5ML

JAN 27, 1997

EQ 300MG BASE/5ML

N74541 001

AUG 05, 1997

SOLUTION; ORAL

CIMETIDINE HCL

ENDO LABS

EQ 300MG BASE/5ML

N74251 001

EQ 300MG BASE/5ML

DEC 22, 1994

EQ 300MG BASE/5ML

N74251 001

EQ 300MG BASE/5ML

DEC 22, 1994

EQ 300MG BASE/5ML

N74664 001

EQ 300MG BASE/5ML

OCT 28, 1997

EQ 300MG BASE/5ML

N74757 001

EQ 300MG BASE/5ML

OCT 17, 1997

EQ 300MG BASE/5ML

N74553 001

EQ 300MG BASE/5ML

JAN 27, 1997

EQ 300MG BASE/5ML

N74541 001

AUG 05, 1997

CIPROFLOXACIN

POWDER FOR RECONSTITUTION; ORAL

CIPRO

+ BAYER

500MG/5ML

N20780 002

SEP 26, 1997

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

LEMMON

EQ 0.5MG BASE/5ML

N73399 001

JUN 30, 1994

EQ 0.5MG BASE/5ML

N73399 001

JUN 30, 1994

TABLET; ORAL

CLEMASTINE FUMARATE

LEMMON

2.68MG

N73283 001

JAN 31, 1992

1.34MG

N73282 001

JAN 31, 1992

2.68MG

N73283 001

JAN 31, 1992

1.34MG

N73282 001

JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

QUAD PHARMS

EQ 150MG BASE/ML

N62795 001

DEC 21, 1987

EQ 150MG BASE/ML

N62795 001

DEC 21, 1987

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

FOUGERA

EQ 1% BASE

N64159 001

JUN 05, 1997

EQ 1% BASE

N62930 001

JUN 28, 1989

EQ 1% BASE

N63304 001

JUL 15, 1997

EQ 1% BASE

N62930 001

JUN 28, 1989

CIPROFLOXACIN

POWDER FOR RECONSTITUTION; ORAL

CIPRO

BAYER

250MG/5ML

N20780 001

SEP 26, 1997

CLOBETASOL PROPIONATE

<u>AB</u>	CREAM; TOPICAL					
	<u>CORMAX</u>					
	HEALTHPOINT					
			0.05%			
<u>AB</u>	GEL; TOPICAL					
	<u>CLOBETASOL PROPIONATE</u>					
	STIEFEL					
			0.05%			
<u>AB</u>	TEMOVATE					
	+ GLAXO WELLCOME					
			0.05%			

CLOCORTOLONE PIVALATE

CREAM; TOPICAL						
CLODERM						
* CTR LABS		0.1%				
+ EM INDS		0.1%				

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>	CAPSULE; ORAL					
	<u>CLOMIPRAMINE HCL</u>					
	INVAMED		25MG			
<u>AB</u>			50MG			
<u>AB</u>			75MG			
<u>AB</u>	LEMMON		25MG			
<u>AB</u>			50MG			
<u>AB</u>			75MG			
<u>AB</u>	NOVOPHARM		25MG			
<u>AB</u>			50MG			
<u>AB</u>			75MG			

CLONAZEPAM

<u>AB</u>	TABLET; ORAL					
	<u>CLONAZEPAM</u>					
	ALPHAPHARM				0.5MG	
					1MG	
					2MG	
					0.5MG	
	BON				1MG	
					2MG	
	INVAMED				0.5MG	
					1MG	
					2MG	
	KLONOPIN					
	+ ROCHE				0.125MG	
					0.25MG	

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	CAPSULE; ORAL					
	<u>CLORAZEPATE DIPOTASSIUM</u>					
	PUREPAC PHARM				7.5MG	
					15MG	
	@				7.5MG	
	@				15MG	
<u>AB</u>	TABLET; ORAL					
	<u>CLORAZEPATE DIPOTASSIUM</u>					
	PUREPAC PHARM				3.75MG	
					7.5MG	

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUMAB PUREPAC PHARM 15MG

@ 3.75MG

@ 7.5MG

@ 15MG

N72332 001

AUG 08, 1988

N72330 001

AUG 08, 1988

N72331 001

AUG 08, 1988

N72332 001

AUG 08, 1988

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ CODEINEAA HALSEY 10MG/5ML; 6.25MG/5ML

@ 10MG/5ML; 6.25MG/5ML

PROMETHAZINE HCL AND CODEINE PHOSPHATEAA HI TECH PHARMA 10MG/5ML; 6.25MG/5ML

N88739 001

DEC 23, 1988

N88739 001

DEC 23, 1988

N40151 001

AUG 26, 1997

CORTICOTROPIN

INJECTABLE; INJECTION

ACTHARAP + RHONE POULENC RORER

+ 40 UNITS/VIAL

@ 25 UNITS/VIAL

@ 25 UNITS/VIAL

@ 40 UNITS/VIAL

CORTICOTROPINAP STERIS

+ 40 UNITS/VIAL

+ 40 UNITS/VIAL

N07504 003

N07504 002

N07504 002

N07504 003

N88772 001

NOV 21, 1984

N88772 001

NOV 21, 1984

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATEBP PUREPAC PHARM 25MG

@ 25MG

@ 25MG

@ 25MG

N80493 001

N80493 001

N80630 001

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE@ ZENITH GOLDLINE 25MG@ ZENITH LABS 25MG@ ZENITH LABS 25MG

N83536 001

N80630 001

N83536 001

CROMOLYN SODIUMAEROSOL, METERED; INHALATION* FINSONS 0.8MG/INH+ RHONE POULENC RORER 0.8MG/INH

N18887 001

DEC 05, 1985

N18887 001

DEC 05, 1985

CAPSULE; INHALATION* FINSONS 20MG+ RHONE POULENC RORER 20MG

N16990 001

N16990 001

SOLUTION; INHALATION* FINSONS 10MG/ML* FINSONS 10MG/ML

N18596 001

MAY 28, 1982

N18596 001

MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%* FINSONS 4%CYANOCOBALAMININJECTABLE; INJECTION* COBAVITE 0.1MG/ML

N83013 001

N83064 001

CYANOCOBALAMIN

INJECTABLE; INJECTION

COBAXITE

@ STERIS

0.1MG/ML

1MG/ML

N83013 001

N83064 001

CYANOCOBALAMIN

@ STERIS

0.1MG/ML

0.1MG/ML

N83120 001

N83120 001

AP

AP

AP

200MG/VIAL

500MG/VIAL

1GM/VIAL

N88372 001

JUL 03, 1986

N88373 001

JUL 03, 1986

N88374 001

SEP 24, 1986

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

DICOPAC KIT

ANERSHAM

MEDI PHYSICS

N/A;N/A;N/A

N/A;N/A;N/A

N17406 001

N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

@ AKORN

1%

1%

N85555 001

N85555 001

AKPENTOLATE

@ AKORN

1%

2%

N40164 001

JAN 13, 1997

N40165 001

JAN 13, 1997

CYCLOGYL

@ ALCON

2%

N84108 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

ASTA

100MG/VIAL

200MG/VIAL

500MG/VIAL

1GM/VIAL

100MG/VIAL

N88371 001

JUL 03, 1986

N88372 001

JUL 03, 1986

N88373 001

JUL 03, 1986

N88374 001

SEP 24, 1986

N88371 001

JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

@ RHONE POULENC RORER

@ WYETH ABERST

@ DAUNORUBICIN HCL

BEDFORD

EQ 20MG BASE/VIAL

EQ 20MG BASE/VIAL

EQ 20MG BASE/VIAL

EQ 20MG BASE/VIAL

EQ 20MG BASE/VIAL

N61876 001

N61876 001

N50484 001

N50484 001

N64103 001

FEB 03, 1995

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

HALSEY

4MG

4MG

N89057 001

JUL 03, 1986

N89057 001

JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL

+ BEDFORD

EQ 20MG BASE/VIAL

N64103 001
FEB 03, 1995DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DDAVP

@ RHONE POULENC RORER

0.01MG/SPRAY

+

0.01MG/SPRAY

N17922 002
FEB 06, 1989
N17922 003
AUG 07, 1996DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+ PHARMACIA AND UPJOHN 100MG

N20705 001
APR 04, 1997DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

ALPHARMA

0.5MG/5ML

@

0.5MG/5ML

N88997 001
OCT 10, 1986
N88997 001
OCT 10, 1986DESERPIDINE

TABLET; ORAL

HARMONYL

* ABBOTT

@

0.25MG
0.25MGN10796 002
N10796 002

GEL; TOPICAL

DECADERM

* MERCK SHARP DOHME

0.1%
0.1%N13538 001
N13538 001DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

SIDMAK LABS NJ

100MG

N71803 001
MAY 29, 1997

150MG

N71804 001
MAY 29, 1997AT

HAUSCH AND LOMB

0.1% EQ 3.5MG BASE/GM;
10,000 UNITS/GMN64063 001
JUL 25, 1994DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

+ RHONE POULENC RORER

0.004MG/ML

N18938 001
MAR 30, 1984DESMOPRESSIN ACETATE

GENSIA

0.004MG/ML

N74888 001
OCT 15, 1997

CREAM; TOPICAL

DECADRON

* MERCK SHARP DOHME

EQ 0.1% PHOSPHATE
EQ 0.1% PHOSPHATEN11983 002
N11983 002

SPRAY, METERED; NASAL

DDAVP

+ RHONE POULENC RORER

0.01MG/SPRAY

N17922 002
FEB 06, 1989

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

STERIS

EQ 4MG PHOSPHATE/ML
EQ 4MG PHOSPHATE/MLN84355 001
N84355 001

DEXTROSE, POTASSIUM CHLORIDEINJECTABLE, INJECTIONPOTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTICCONTAINERMCGAW

5GM/100ML; 37MG/100ML

N19699 001

SEP 29, 1989

5GM/100ML; 37MG/100ML

N19699 001

SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTICCONTAINERMCGAW

5GM/100ML; 75MG/100ML

N19699 002

SEP 29, 1989

5GM/100ML; 75MG/100ML

N19699 002

SEP 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTICCONTAINERMCGAW

5GM/100ML; 110MG/100ML

N19699 003

SEP 29, 1989

5GM/100ML; 110MG/100ML

N19699 003

SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTICCONTAINERMCGAW

5GM/100ML; 220MG/100ML

N19699 005

SEP 29, 1989

5GM/100ML; 220MG/100ML

N19699 005

SEP 29, 1989

DEXTROSE, POTASSIUM CHLORIDE, SODIUM CHLORIDEINJECTABLE, INJECTIONDEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE0.075%MCGAW

5GM/100ML; 75MG/100ML;

200MG/100ML

5GM/100ML; 75MG/100ML;

200MG/100ML

5GM/100ML; 75MG/100ML;

200MG/100ML

5GM/100ML; 150MG/100ML;

200MG/100ML

5GM/100ML; 150MG/100ML;

200MG/100ML

5GM/100ML; 150MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

DEXTROSE, POTASSIUM CHLORIDE, SODIUM CHLORIDEINJECTABLE, INJECTIONDEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE0.224% IN PLASTIC CONTAINERMCGAW

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

5GM/100ML; 220MG/100ML;

200MG/100ML

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONDEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.075%

MCGAW

5GM/100ML; 75MG/100ML;

450MG/100ML N18268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

MCGAW

5GM/100ML; 150MG/100ML;

450MG/100ML

5GM/100ML; 150MG/100ML;

450MG/100ML N18268 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.22% IN PLASTIC CONTAINER

MCGAW

5GM/100ML; 220MG/100ML;

450MG/100ML

5GM/100ML; 220MG/100ML;

450MG/100ML N18268 002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.3% IN PLASTIC CONTAINER

MCGAW

5GM/100ML; 300MG/100ML;

450MG/100ML

5GM/100ML; 300MG/100ML;

450MG/100ML N18268 003

DEXTROSE; SODIUM CHLORIDEINJECTABLE; INJECTIONDEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MCGAW

10GM/100ML; 900MG/100ML

10GM/100ML; 900MG/100ML

10GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

5GM/100ML; 900MG/100ML

DIAZEPAMGEL; RECTALDIATAT

+ ATHENA

2.5MG/0.5ML

5MG/ML

10MG/2ML

15MG/3ML

20MG/4ML

INJECTABLE; INJECTIONDIAZEPAM

ABBOTT

5MG/ML

AP

5MG/ML

AP

5MG/ML

AP

5MG/ML

TABLET; ORALDIAZEPAM

HALSEY

2MG

5MG

10MG

2MG

5MG

10MG

10MG

2MG

5MG

10MG

N20648 001
JUL 29, 1997
N20648 002
JUL 29, 1997
N20648 003
JUL 29, 1997
N20648 004
JUL 29, 1997
N20648 005
JUL 29, 1997N72079 001
DEC 20, 1988
N70912 001
AUG 28, 1986
N70912 001
AUG 28, 1986
N72079 001
DEC 20, 1988N70987 001
AUG 15, 1986
N70996 001
AUG 15, 1986
N70956 001
AUG 15, 1986
N70987 001
AUG 15, 1986
N70996 001
AUG 15, 1986
N70956 001
AUG 15, 1986
N70362 001
SEP 04, 1985
N70360 001
SEP 04, 1985
N70361 001
SEP 04, 1985
N70362 001
SEP 04, 1985

DIAZEPAM

TABLET; ORAL
DIAZEPAM
@ ZENITH LABS

2MG
5MG

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM
COPELEY PHARM

AB 25MG
AB 50MG
AB 75MG

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL
WEST WARD

AB 10MG

SYRUP; ORAL

AA BENTYL
+ AA HOECHST MARION RESSL

10MG/5ML
10MG/5ML

AA DICYCLOMINE HCL
ALPHARMA

10MG/5ML
10MG/5ML

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL
LILLY

1MG
5MG
1MG
5MG
0.5MG

DIETHYLSTILBESTROL

TABLET; ORAL
STILBESTROL
@ TABLICAPS
STILBESTROL TAB
SMITH MILLER PATCH

0.5MG
25MG
N83004 001
N06194 001

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
DANBURY PHARMA

AB 250MG
AB 500MG

N74400 001
JUL 17, 1997
N74400 002
JUL 17, 1997

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN
ABBOTT

AP 0.25MG/ML

N40093 001
MAY 16, 1996
N40093 001
MAY 16, 1996

AP SANOFI WINTHROP

0.25MG/ML

AP DIGOXIN PEDIATRIC
ABBOTT

0.1MG/ML

N40092 001
APR 25, 1996
N40092 001
APR 25, 1996

AP SANOFI WINTHROP

0.1MG/ML

TABLET; ORAL

LANOXIN

@ GLAXO WELLCOME

0.0625MG

N20405 001
SEP 30, 1997
N20405 002
SEP 30, 1997
N20405 003
SEP 30, 1997
N20405 004
SEP 30, 1997
N20405 005
SEP 30, 1997
N20405 006
SEP 30, 1997

@

+

@

@

N04041 004
N04041 005
N04041 004
N04041 005
N83004 001

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

> DLT > AB * HOECHST MARION RSSL 60MG

> DLT > AB1 + 60MG

> ADD > AB * 90MG

> DLT > AB1 + 90MG

> DLT > AB1 + 90MG

> ADD > AB * 120MG

> DLT > AB1 + 120MG

> ADD > AB1 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 180MG

> ADD > AB2 + 240MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

> ADD > AB2 + 120MG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

> ADD > AB1 TEVA 60MG

> ADD > AB1 90MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

> ADD > AB1 120MG

N74079 001
NOV 30, 1993
N74079 002
NOV 30, 1993
N74079 003
NOV 30, 1993

N20792 001
SEP 05, 1997
N74894 001
AUG 26, 1997

N84767 001
N84767 001

N05939 001
N05939 001

N80845 002
N80845 001
N80845 002
N80845 001
N80762 001
N80762 002
N80762 001
N80762 002

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP BENADRYL 10MG/ML
 AP * PARKE DAVIS 50MG/ML
 AP + 10MG/ML

AP BENADRYL PRESERVATIVE FREE 50MG/ML
 + PARKE DAVIS

AP DIPHENHYDRAMINE HCL 50MG/ML
 AP FUJISAWA 50MG/ML
 AP INTL MEDICATION 50MG/ML
 AP STERIS 10MG/ML
 AP 10MG/ML
 + 10MG/ML
 @ 10MG/ML

AP DIPHENHYDRAMINE HCL PRESERVATIVE FREE 50MG/ML
 AP FUJISAWA 50MG/ML
 AP INTL MEDICATION 50MG/ML
 AP STERIS 50MG/ML

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB CHELSEA LABS 50MG

N87160 001
 JUN 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

@ LILLY

250MG

250MG

N50678 001
 JUN 19, 1995
 N50678 001
 JUN 19, 1995

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

ABBOTT

EQ 12.5MG BASE/ML

N74292 001

FEB 16, 1995

N74292 001

FEB 16, 1995

SANOFI WINTHROP

EQ 12.5MG BASE/MLDOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION

ANZEMET
 + HOECHST MARION RSSL EQ 20MG BASE/ML

N20624 001
 SEP 11, 1997

TABLET; ORAL

ANZEMET

HOECHST MARION RSSL EQ 50MG BASE

N20623 001
 SEP 11, 1997

EQ 100MG BASE

N20623 002
 SEP 11, 1997

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

PFIZER

EQ 1MG BASE

N19668 001
 NOV 02, 1990

EQ 8MG BASE

N19668 004
 NOV 02, 1990

EQ 1MG BASE

N19668 001
 NOV 02, 1990

EQ 8MG BASE

N19668 004
 NOV 02, 1990

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

PUREPAC PHARM

EQ 100MG BASE

N72110 001

EQ 100MG BASE

N72110 001
 SEP 08, 1988

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

PARKE DAVIS

EQ 100MG BASE

N62653 001

OCT 30, 1985

WARNER CHILCOTT

EQ 100MG BASE

N62653 001
 OCT 30, 1985

DROPERIDOLINJECTABLE; INJECTIONAP ABBOTT2.5MG/MLN72272 001

AUG 31, 1995

2.5MG/MLN72272 001

AUG 31, 1995

AP SANOFI WINTHROPECONAZOLE NITRATECREAM; TOPICAL
SPECTAZOLE
+ J AND J

1%

N18751 001

DEC 23, 1982

* JOHNSON RW

1%

N18751 001

DEC 23, 1982

ERGOLOID MESYLATESTABLET; SUBLINGUALHYDROGENATED ERGOT ALKALOIDS
@ ZENITH GOLDLINE
0.5MG
0.5MGN87186 001N87186 001ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN
ALTANA2%N64184 001

SEP 30, 1997

SOLUTION; TOPICALERYTHROMYCIN
ALTANA2%N64187 001

SEP 30, 1997

2%N64127 001

FEB 14, 1997

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE
@ ZENITH GOLDLINE

EQ 250MG BASE

EQ 250MG BASE

N62237 001N62237 001ESTAZOLAMTABLET; ORALESTAZOLAM
ROYCE LABS1MGN74818 001

AUG 19, 1997

2MGN74818 002

AUG 19, 1997

1MGN74921 001

JUL 10, 1997

2MGN74921 002

JUL 10, 1997

1MGN74826 001

JUL 03, 1997

2MGN74826 002

JUL 03, 1997

PROSOM
ABBOTT1MGN19080 001

DEC 26, 1990

2MGN19080 002

DEC 26, 1990

ESTRADIOLTABLET; ORALESTRADIOL
BARR0.5MGN40197 001

OCT 22, 1997

1MGN40197 002

OCT 22, 1997

2MGN40197 003

OCT 22, 1997

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL-21ALESSE
+ WYETH AYERST

0.02MG; 0.1MG

N20683 001

MAR 27, 1997

TABLET; ORAL-28ALESSE
WYETH AYERST

0.02MG; 0.1MG

N20683 002

MAR 27, 1997

ETODOLAC

CAPSULE; ORAL

ETODOLAC
ENDO PHARMS

AB 200MG

AB 300MG

AB 200MG GENEVA PHARMS

AB 300MG

AB 200MG INVAMED

AB 300MG

AB 200MG MYLAN

AB 300MG

AB 200MG ZENITH GOLDLINE

AB 300MG

LODINE

AB 200MG WYETH AYERST

AB 300MG +

N74842 001

JUL 17, 1997

N74842 002

JUL 17, 1997

N74840 001

AUG 29, 1997

N74840 002

AUG 29, 1997

N74942 001

SEP 30, 1997

N74942 002

SEP 30, 1997

N74932 001

MAY 16, 1997

N74932 002

MAY 16, 1997

N74899 001

JUL 08, 1997

N74899 002

JUL 08, 1997

N18922 002

JAN 31, 1991

N18922 003

JAN 31, 1991

N74927 001

OCT 30, 1997

N74841 001

JUN 27, 1997

N74903 001

APR 11, 1997

N74839 001

JUL 11, 1997

N74846 001

FEB 28, 1997

N74819 001

FEB 28, 1997

N74892 001

APR 16, 1997

N74883 001

FEB 28, 1997

ETODOLAC

TABLET; ORAL

LODINE

AB 400MG WYETH AYERST

ETOPOSIDE

AB 20MG/ML INJECTABLE; INJECTION

ETOPOSIDE

IMMUNEX

AB 20MG/ML PIERRE FABRE

AB 20MG/ML SUPERGEN

FENOLDOPAM MESYLATE

AB EQ 10MG BASE/ML INJECTABLE; INJECTION

CORLOPAM

+ NEUREX

FENTANYL CITRATE

AB EQ 0.05MG BASE/ML INJECTABLE; INJECTION

FENTANYL CITRATE

AB EQ 0.05MG BASE/ML ABBOTT

AB EQ 0.05MG BASE/ML STERLING WINTHROP

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

3M

3M

3M

N18922 004

JUL 29, 1993

N74513 001

MAR 14, 1996

N74813 001

JUL 09, 1997

N74513 001

MAR 14, 1996

N19922 001

SEP 23, 1997

N72786 001

SEP 24, 1991

N72786 001

SEP 24, 1991

N18830 004

AUG 23, 1988

N18830 001

OCT 31, 1985

N18830 003

JUN 03, 1988

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
3M

50MG
100MG
150MG

+

N18830 004
AUG 23, 1988
N18830 001
OCT 31, 1985
N18830 003
JUN 03, 1988

FLUNISOLIDE

SPRAY, METERED; NASAL

NASAREL

BX +

0.025MG/SPRAY

N20409 001
MAR 08, 1995
N20409 001
MAR 08, 1995

BX + SYNTEX

0.025MG/SPRAY

FLUCINOLONE ACETONIDEFLUCONAZOLE

INJECTABLE; INJECTION

DIFLUCAN
* PFIZER

200MG/100ML

N19950 001
JAN 29, 1990

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PFIZER

200MG/100ML

N19950 003
SEP 29, 1992

2MG/ML

N19950 005
JUL 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ PFIZER

200MG/100ML

N19950 001
JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ PFIZER

200MG/100ML

N19950 002
JAN 29, 1990

2MG/ML

N19950 004
JUL 08, 1994

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

ICN

250MG

N17001 001

500MG

N17001 002

250MG

N17001 001

500MG

N17001 002

FLUNISOLIDE

SPRAY, METERED; NASAL

NASALIDE

BX +

0.025MG/SPRAY

N18148 001

BX + SYNTEX

0.025MG/SPRAY

N18148 001

CREAM; TOPICAL

FLUCOCET

@ ALPHARMA

0.025%

N88360 001
JAN 16, 1984

0.025%

N88360 001
JAN 16, 1984

FLUCINOLONE ACETONIDE

@ ALPHARMA

0.01%

N88361 001
JAN 16, 1984

0.01%

N88361 001
JAN 16, 1984

SYNALAR

+ MEDICIS

0.01%

N12787 004

0.025%

N12787 002

0.025%

N12787 005

0.01%

N12787 004

0.025%

N12787 002

0.025%

N12787 005

SYNALAR-HP

+ MEDICIS

0.2%

N16161 002

+ SYNTEX

0.2%

N16161 002

SYNALAR

+ MEDICIS

0.025%

N13960 001

+ SYNTEX

0.025%

N13960 001

SOLUTION; TOPICAL

SYNALAR

0.01%

N15296 001

+ MEDICIS

0.01%

N15296 001

+ SYNTEX

0.01%

N15296 001

FLUCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

+ MEDICIS

N60700 001

0.025%; EQ 3.5MG BASE/GM

FLUOCINOLONE ACETONIDE, NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR
+ SYNTEX

0.025%;EQ 3.5MG BASE/GM N60700 001

FLUOCINONIDE

CREAM; TOPICAL
LIDEX
+ MEDICIS
AB * SYNTEX
AB * SYNTEX
LIDEX-E
AB MEDICIS
AB * SYNTEX

0.05%
0.05%
0.05%
0.05%

N16908 002
N16908 002
N16908 003
N16908 003

GEL; TOPICAL
FLUOCINONIDE
TARO

0.05%

N74935 001
JUL 29, 1997

LIDEX
+ MEDICIS
AB * SYNTEX
AB * SYNTEX

0.05%
0.05%

N17373 001
N17373 001

OINTMENT; TOPICAL

FLUOCINONIDE
ALTANA

0.05%

N74905 001
AUG 26, 1997

LIDEX
+ MEDICIS
AB * SYNTEX
AB * SYNTEX

0.05%
0.05%

N16909 002
N16909 002

SOLUTION; TOPICAL

LIDEX
+ MEDICIS
AT * SYNTEX
AT * SYNTEX

0.05%
0.05%

N18849 001
APR 06, 1984
N18849 001
APR 06, 1984

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP
+ LILLY
+ OCLASSEN
+

0.025%
0.05%
0.025%
0.05%

N12806 003
N12806 002
N12806 003
N12806 002

FLURANDRENOLIDE

LOTION; TOPICAL
CORDRAN
AT * LILLY
AT * OCLASSEN

0.05%
0.05%

N13790 001
N13790 001

OINTMENT; TOPICAL
CORDRAN
+ LILLY
+ OCLASSEN
+

0.025%
0.05%
0.025%
0.05%

N12806 004
N12806 001
N12806 004
N12806 001

TAPE; TOPICAL
CORDRAN
+ LILLY
+ OCLASSEN

0.004MG/SQ CM
0.004MG/SQ CM

N16455 001
N16455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL
HALSEY

15MG

N71808 001

JAN 07, 1988

30MG

N71809 001

JAN 07, 1988

15MG

N71808 001

JAN 07, 1988

30MG

N71809 001

JAN 07, 1988

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
SIDMAK LABS NJ

50MG

N74647 001

APR 01, 1997

100MG

N74647 002

APR 01, 1997

100MG

N74560 002

MAY 16, 1997

WARNER CHILCOTT

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA DANBURY PHARMA

AA +

AA FOLVITE

AA * LEDERLE

®

1MG1MG1MG1MGN80680 001
N80680 001N05897 004
N05897 004FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

FOLLISTIM

ORGANON

75 IU/VIAL

150 IU/VIAL

N20582 001
SEP 29, 1997
N20582 002
SEP 29, 1997

GONAL-F

SERONO

75 IU/VIAL

150 IU/VIAL

N20378 001
SEP 29, 1997
N20378 002
SEP 29, 1997FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABBOTT

10MG/ML10MG/ML10MG/ML10MG/ML10MG/ML10MG/ML10MG/MLN70578 001
JUL 08, 1987
N72080 001
AUG 13, 1991
N74337 001
OCT 31, 1994
N74337 001
OCT 31, 1994
N70578 001
JUL 08, 1987
N72080 001
AUG 13, 1991GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

AT NMC

EQ 0.1% BASEN62471 001
SEP 27, 1983

OINTMENT; TOPICAL

GENTAMICIN SULFATE

® ALPHARMA

EQ 0.1% BASEN62496 001
MAR 14, 1984
N62496 001
MAR 14, 1984

AT NMC

EQ 0.1% BASEGLIPIZIDE

TABLET; ORAL

GLIPIZIDE

DURAMED

5MG10MG5MG10MGN74550 001
SEP 11, 1997
N74550 002
SEP 11, 1997
N74378 001
NOV 28, 1994
N74378 002
NOV 28, 1994
N74378 001
NOV 28, 1994
N74378 002
NOV 28, 1994
N74378 001
NOV 28, 1994
N74378 002
NOV 28, 1994
N74619 001
APR 04, 1997
N74619 002
APR 04, 1997

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

GLUTETHIMIDE

TABLET; ORAL

GLUTETHIMIDE

HAUSEY

500MG

500MG

N89459 001
OCT 10, 1986
N89459 001
OCT 10, 1986

®

EQ 0.1% BASE

CREAM; TOPICAL

GENTAMICIN SULFATE

® ALPHARMA

N62471 001
SEP 27, 1983

GRISOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V
+ J AND J

125MG/5ML
125MG/5ML
125MG/5ML
125MG/5ML

N50448 001
N62483 001
JAN 26, 1984
N50448 001
N62483 001
JAN 26, 1984

* JOHNSON RW

TABLET; ORAL
GRIFULVIN V
J AND J

AB
AB
AB
AB

250MG
250MG
500MG
500MG
125MG
125MG
250MG
250MG
500MG
500MG
500MG
125MG
125MG

N60618 002
N62279 002
N60618 003
N62279 003
N60618 001
N62279 001
N60618 002
N62279 002
N60618 003
N62279 003
N60618 001
N62279 001

JOHNSON RW

AB
AB
AB
AB

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL
AMIDE PHARM

AB
AB
AB
AB
AB
AB

EQ 1MG BASE
EQ 2MG BASE
EQ 1MG BASE
EQ 2MG BASE
EQ 1MG BASE
EQ 2MG BASE

N74673 001
FEB 28, 1997
N74673 002
FEB 28, 1997
N74796 001
JAN 27, 1997
N74796 002
JAN 27, 1997
N74762 001
JUN 25, 1997
N74762 002
JUN 25, 1997

HALCINONIDE

CREAM; TOPICAL
HALOG
WESTWOOD SQUIBB

0.025%

N17818 001

HALCINONIDE

CREAM; TOPICAL
HALOG
@ WESTWOOD SQUIBB

0.025%

N17818 001

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALDOL
+ JOHNSON RW

EQ 50MG BASE/ML
EQ 100MG BASE/ML
EQ 100MG BASE/ML
EQ 50MG BASE/ML

N18701 001
JAN 14, 1986
N18701 002
JAN 31, 1997
N18701 002
OCT 31, 1989
N18701 001
JAN 14, 1986

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER
FUJISAWA

AP
AP

10 UNITS/ML
100 UNITS/ML
10 UNITS/ML
100 UNITS/ML

N17029 017
DEC 05, 1985
N17029 018
DEC 05, 1985
N17029 017
DEC 05, 1985
N17029 018
DEC 05, 1985

HEPARIN LOCK FLUSH
ABBOTT

AP

10 UNITS/ML

N40082 001

AP

10 UNITS/ML

N88097 001

AP

10 UNITS/ML

N88346 001

AP

100 UNITS/ML

N40082 002

AP

100 UNITS/ML

N88098 001

AP

100 UNITS/ML

N88347 001

MAY 18, 1983

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH
SANOFI WINTHROP

AP

10 UNITS/MLN40082 001
FEB 28, 1995

AP

100 UNITS/MLN40082 002
FEB 28, 1995

AP

10 UNITS/MLN88097 001
APR 28, 1983

AP

10 UNITS/MLN88346 001
MAY 18, 1983

AP

100 UNITS/MLN88098 001
APR 28, 1983

AP

100 UNITS/MLN88347 001
MAY 18, 1983HEPARIN SODIUM

ABBOTT

AP

2,500 UNITS/MLN88099 001
APR 28, 1983

AP

5,000 UNITS/MLN88100 001
APR 28, 1983

AP

10,000 UNITS/MLN40095 001
JUL 26, 1996

AP

20,000 UNITS/MLN17029 004
N40095 001

AP

10,000 UNITS/ML

JUL 26, 1996

AP

1,000 UNITS/MLN17064 002
JUL 26, 1996

AP

1,000 UNITS/MLN88099 001
APR 28, 1983

AP

2,500 UNITS/MLN88100 001
APR 28, 1983

AP

5,000 UNITS/MLN88100 001
APR 28, 1983

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

ABBOTT

AP

10,000 UNITS/100MLN19339 003
MAR 27, 1985

AP

10,000 UNITS/100MLN19339 003
MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

ABBOTT

AP

5,000 UNITS/100MLN19339 001
MAR 27, 1985

AP

5,000 UNITS/100MLN19339 001
MAR 27, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

ABBOTT

AP

5,000 UNITS/100MLN19339 004
MAR 27, 1985HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

AP

ABBOTT

10,000 UNITS/100MLN19339 002
MAR 27, 1985

AP

5,000 UNITS/100MLN19339 004
MAR 27, 1985

AP

10,000 UNITS/100MLN19339 002
MAR 27, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP + ABBOTT

10,000 UNITS/MLN89522 001
MAY 04, 1987

AP

STERLING WINTHROP

10,000 UNITS/MLN89522 001
MAY 04, 1987

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

AA

+ DUPONT MERCK

1.5MG/5ML; 5MG/5MLN05213 002
JUL 26, 1988

AA

+ ENDO PHARMS

1.5MG/5ML; 5MG/5MLN05213 002
JUL 26, 1988

AA

HYDROPAINE

1.5MG/5ML; 5MG/5MLN88066 001
JUN 28, 1985

HAISEY

AP

1.5MG/5ML; 5MG/5MLN88066 001
JUN 28, 1985

AP

1.5MG/5ML; 5MG/5MLN88066 001
JUN 28, 1985

TABLET; ORAL

HYCODAN

AA

+ DUPONT MERCK

1.5MG; 5MGN05213 001
JUL 26, 1988

AA

+ ENDO PHARMS

1.5MG; 5MGN05213 001
JUL 26, 1988

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

AP

LUITPOLD

20MG/MLN40136 001
JUN 30, 1997

TABLET; ORAL

HYDRALAZINE HCL

AA

HAISEY

25MGN89130 001
JAN 15, 1986

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

HAUSEY

100MG

AA

®

25MG

®

100MG

®

PUREPAC PHARM

25MG

AA

®

25MG

®

10MG

®

ZENITH GOLDLINE

25MG

®

50MG

®

100MG

®

ZENITH LABS

25MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

®

25MG

®

100MG

®

ZENITH LABS

100MG

AA

HYDROCHLOROTHIAZIDE, METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE
 @ ZENITH GOLDLINE 25MG; 250MG
 @
 @ 30MG; 500MG
 @ 50MG; 500MG
 @ ZENITH LABS
 @ 15MG; 250MG
 @ 25MG; 250MG
 @ 30MG; 500MG
 @ 50MG; 500MG

N71459 001
 MAR 08, 1988
 N71460 001
 MAR 08, 1988
 N71461 001
 MAR 08, 1988
 N71458 001
 MAR 08, 1988
 N71459 001
 MAR 08, 1988
 N71460 001
 MAR 08, 1988
 N71461 001
 MAR 08, 1988

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
 UNIRETIC
 SCHWARZ PHARMA 12.5MG; 7.5MG
 + 25MG; 15MG

N20729 001
 JUN 27, 1997
 N20729 002
 JUN 27, 1997

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
 @ ZENITH GOLDLINE 25MG; 40MG
 @
 @ 25MG; 80MG
 @ ZENITH LABS 25MG; 40MG
 @ 25MG; 80MG

N71552 001
 DEC 01, 1988
 N71553 001
 DEC 01, 1988
 N71552 001
 DEC 01, 1988
 N71553 001
 DEC 01, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 HYDROCHLOROTHIAZIDE W/ RESERPINE
 @ ZENITH GOLDLINE 25MG; 0.1MG

N83572 001

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 HYDROCHLOROTHIAZIDE W/ RESERPINE
 @ ZENITH GOLDLINE 25MG; 0.125MG
 @ 50MG; 0.1MG
 @ ZENITH LABS
 @ 25MG; 0.125MG
 @ 50MG; 0.125MG
 @ 25MG; 0.1MG
 @ 50MG; 0.1MG

N83571 001
 N83568 001
 N83573 001
 N83571 001
 N83573 001
 N83572 001
 N83568 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
 @ ZENITH GOLDLINE 25MG; 25MG

N87004 002
 MAY 24, 1982
 N87004 002
 MAY 24, 1982

AB ZENITH LABS 25MG; 25MG

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 AB GENEVA PHARMS 25MG; 37.5MG
 AB NOVARTIS 25MG; 37.5MG

N74821 001
 JUN 05, 1997
 N74857 001
 SEP 09, 1997

TABLET; ORAL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 B* PAR PHARM 50MG; 75MG

N72337 001
 MAY 11, 1988

HYDROCODONE BITARTRATE, IBUPROFEN

TABLET; ORAL
 VICOPROFEN
 + KNOLL PHARM 7.5MG; 200MG

N20716 001
 SEP 23, 1997

HYDROCORTISONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
HYCOMINE
* DUPONT MERCK
+ ENDO PHARMS
HYCOMINE PEDIATRIC
DUPONT MERCK
ENDO PHARMS

5MG/5ML; 25MG/5ML

5MG/5ML; 25MG/5ML

2.5MG/5ML; 12.5MG/5ML

2.5MG/5ML; 12.5MG/5ML

N19410 001
AUG 17, 1990N19410 001
AUG 17, 1990N19411 001
AUG 17, 1990N19411 001
AUG 17, 1990HYDROCORTISONE

CREAM; TOPICAL

DERMACORT
MONARCH PHARMS
SOLVAY

HYDROCORTISONE

@ ALPHARMA

1%

1%

2.5%

2.5%

N83011 002

N83011 002

N89754 001

FEB 01, 1989

N89754 001

FEB 01, 1989

PROCTOCORT

MONARCH PHARMS

SOLVAY

SYNACORT

MEDICIS

@

SYNTEX

@

1%

1%

1%

2.5%

0.5%

1%

2.5%

0.5%

N83011 001

N83011 001

N87458 001

N87457 001

N87459 001

N87458 001

N87457 001

N87459 001

TABLET; ORAL

HYDROCORTISONE

PUREPAC PHARM

10MG

20MG

10MG

20MG

N84247 003

AUG 31, 1982

N84247 002

N84247 003

AUG 31, 1982

N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; AURICULAR (OTIC)

CORTISPORIN

AT + MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N50479 001

OTOCORT

@ STERIS

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N60730 002

SOLUTION/DROPS; OTIC

CORTISPORIN

AT + GLAXO WELLCOME

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N50479 001

OTOCORT

@ STERIS

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N60730 002

SUSPENSION/DROPS; AURICULAR (OTIC)

OTOCORT

@ STERIS

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62521 001

JUL 11, 1985

PEDIOTIC

AT MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62822 001

SEP 29, 1987

SUSPENSION/DROPS; OTIC

OTOCORT

@ STERIS

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62521 001

JUL 11, 1985

PEDIOTIC

AT GLAXO WELLCOME

1%;EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62822 001

SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

@ BIOGLAN

@ VIVAN

1%;10%

1%;10%

N86008 001

N86008 001

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN '97 - OCT '97

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HEMSOL-HC
AT ABLE

1%

+

N81274 001
JUN 19, 1992
N81274 001
JUN 19, 1992

AT + HYDROCORTISONE ACETATE
PUREFAC PHARM

1%
1%

N86052 001
N86052 001

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

AKORN

25MG/ML

N9637 001

50MG/ML

N9637 002

25MG/ML

N9637 001

50MG/ML

N9637 002

25MG/ML

N83759 001

50MG/ML

N83759 002

50MG/ML

50MG/ML

N8228 004

50MG/ML

N8228 004

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
CORTISPORIN
+ GLAXO WELLCOME

0.5%; EQ 3.5MG BASE/GM;
10,000 UNITS/GM

N50218 001
AUG 09, 1985

0.5%; EQ 3.5MG BASE/GM;
10,000 UNITS/GM

N50218 001
AUG 09, 1985

HYDROCORTISONE BUTEPATE

CREAM; TOPICAL
PANDEL

0.1%

N20453 001
FEB 28, 1997

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOD LIFOCREAM
YAMANOUCHI

0.1%

N20769 001
SEP 08, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

ELKINS SINN

AP EQ 1GM BASE/VIAL
EQ 1GM BASE/VIAL

N87569 001
N87569 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

@ ZENITH GOLDLINE 50MG; 0.125MG

N8932 001
JAN 11, 1985

N8932 001
JAN 11, 1985

BP ZENITH LABS 50MG; 0.125MG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

ABBOTT

10MG/ML

N74598 001
JUN 19, 1997

AP SANOFI

10MG/ML

N74598 001
JUN 19, 1997

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

ABBOTT

25MG/ML

N87416 001

50MG/ML

N87546 001

25MG/ML

N87416 001

50MG/ML

N87546 001

TABLET; ORAL

HYDROXYZINE HCL

HALSEY

25MG

N89117 001
MAY 02, 1988

IFOSFAMIDEINJECTABLE; INJECTION

IFEX
 * BRISTOL MYERS SQUIBB 1GM/VIAL
 * 3GM/VIAL
 @ 1GM/VIAL
 @ 3GM/VIAL

N19763 001
 DEC 30, 1988
 N19763 002
 DEC 30, 1988
 N19763 001
 DEC 30, 1988
 N19763 002
 DEC 30, 1988

IFOSFAMIDE; MESNAINJECTABLE; INJECTION

IFEX/MESNEX KIT
 + BRISTOL MYERS SQUIBB 1GM/VIAL; 100MG/ML
 + 3GM/VIAL; 100MG/ML

N19763 003
 OCT 10, 1992
 N19763 004
 OCT 10, 1992

IMIQUIMOD

CREAM; TOPICAL
 ALDARA
 + 3M

5%

N20723 001
 FEB 27, 1997

INDAPAMIDETABLET; ORAL

INDAPAMIDE
 MYLAN
 AB 1.25MG
 AB 1.25MG
 AB 2.5MG

N74461 002
 MAR 26, 1997
 N74665 001
 APR 04, 1997
 N74665 002
 APR 04, 1997

INDIUM IN-111 OXYQUINOLINEINJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE
 AMERSHAM
 1mCi/ML

N19044 001
 DEC 23, 1985

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
 INDIUM IN-111 OXYQUINOLINE
 MEDI PHYSICS
 1mCi/ML

N19044 001
 DEC 23, 1985

INDOCYANINE GREENINJECTABLE; INJECTION

CARDIO-GREEN
 + AKORN
 + BECTON DICKINSON
 + 25MG/VIAL
 + 50MG/VIAL
 + 25MG/VIAL
 + 50MG/VIAL

N11525 001
 N11525 002
 N11525 001
 N11525 002

IODIXANOLINJECTABLE; INJECTION

VISIPAQUE 270
 NYCOMED

N20808 001
 AUG 29, 1997

55%

65.2%

N20808 002
 AUG 29, 1997

IODOHIPPURATE SODIUM, I-131INJECTABLE; INJECTION

HIPPUTOPE
 BRACCO
 @ 1-2mCi/VIAL
 @ 1-2mCi/VIAL
 IODOHIPPURATE SODIUM I 131
 @ CIS
 @ 0.2mCi/ML
 @ 0.2mCi/ML
 @ 0.2mCi/ML

N15419 002
 N15419 002
 N17313 001
 N17313 001

IOPAMIDOLINJECTABLE; INJECTION

IOPAMIDOL-250
 FUJISAWA

N74679 001
 APR 02, 1997

51%

IOPAMIDOL-300

ABBOTT

N74638 001
 APR 30, 1997

61%

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-300

FUJISAWA

61%

N74679 002
APR 02, 1997

IOPAMIDOL-300 IN PLASTIC CONTAINER

ABBOTT

61%

N74637 001
APR 03, 1997

IOPAMIDOL-370

FUJISAWA

76%

N74679 003
APR 02, 1997

ISOVUE-250

BRACCO

51%

N18735 007
JUL 06, 1992

AP +

51%

N20327 002
OCT 12, 1994

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO

3GM/PACKET
3GM/PACKET

N12968 001
N12968 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ATROVENT

AN + BOEHRINGER INGELHEIM 0.02%

AN IPRATROPIUM BROMIDE

DEY

0.02%

N20228 001
SEP 29, 1993

IRBESARTAN

TABLET; ORAL

AVAPRO

SANOFI

75MG

150MG

300MG

+

N20757 001
SEP 30, 1997
N20757 002
SEP 30, 1997
N20757 003
SEP 30, 1997

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL

ALPHARMA

1%
1%

N87101 001
N87101 001

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

* MERCK SHARP DOHME

0.025%
0.025%

N10656 001
N10656 001

ISONIAZID

SYRUP; ORAL

ISONIAZID

AA + CAROLINA MEDCL

50MG/5ML

N88235 001
NOV 10, 1983

50MG/5ML

N88235 001
NOV 10, 1983

AA MIKART

50MG/5ML

N81118 001
JUL 21, 1997

AA LANIAZID

LANNETT

50MG/5ML

N89243 001
FEB 03, 1986

50MG/5ML

N89243 001
FEB 03, 1986

TABLET; ORAL

ISONIAZID

MIKART

100MG

N40090 001
JUN 26, 1997

300MG

N40090 002
JUN 26, 1997

@ ZENITH GOLDLINE

@ ZENITH LABS

@ ZENITH LABS

100MG

300MG

100MG

300MG

300MG

300MG

N83610 001
N83610 001
N83610 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

BN + 3M

0.12MG/INH

N10375 004

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

BN 3M 0.12MG/INH
 @ ALPHARMA 0.12MG/INH
 0.12MG/INH

INJECTABLE; INJECTION

ISUPREL

AP 0.2MG/ML
 AP + ABBOTT 0.2MG/ML
 AP * SANOFI WINTHROP 0.2MG/ML

N10375 004
 N85904 001
 N85904 001

N10515 001
 N10515 001

AB N10375 004
 AB N85904 001
 AB N85904 001

AB MYLAN 10MG

AB ROXANE 10MG

AB TEVA 10MG

AB TORADOL 10MG
 AB + SYNTEX 10MG

N74955 001
 SEP 19, 1997
 N74761 001
 MAY 16, 1997
 N74790 001
 JUN 26, 1997
 N74754 001
 MAY 16, 1997

N19645 001
 DEC 20, 1991

ITRACONAZOLE

SOLUTION; ORAL

SPORANOX

+ JANSSEN

10MG/ML

N20657 001
 FEB 21, 1997

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

+ GLAXO WELLCOME

150MG;300MG

N20857 001
 SEP 26, 1997

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP ABBOTT

EQ 50MG BASE/ML

N74549 001
 JUN 27, 1996

EQ 100MG BASE/ML

N74549 002
 JUN 27, 1996

EQ 50MG BASE/ML

N74549 001
 JUN 27, 1996

EQ 100MG BASE/ML

N74549 002
 JUN 27, 1996

N20406 001
 MAY 10, 1995
 N20406 002
 MAY 10, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP ABBOTT

15MG/ML

N74801 001
 JUN 05, 1997

15MG/ML

N74802 001
 JUN 05, 1997

30MG/ML

N74801 002
 JUN 05, 1997

30MG/ML

N74802 002
 JUN 05, 1997

N20406 001
 MAY 10, 1995
 N20406 002
 MAY 10, 1995

N20726 001
 JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP + ABBOTT
AP + BEDFORD
*
AP GENSLA
AP IMMUNEX
AP PHARMACHEMIE
AP

EQ 10MG BASE/VIAL
EQ 200MG BASE/VIAL
EQ 200MG BASE/VIAL
EQ 350MG BASE/VIAL
EQ 350MG BASE/VIAL
EQ 50MG BASE/VIAL
EQ 100MG BASE/VIAL

N40147 001
JUN 25, 1997
N40056 001
MAY 23, 1995
N40056 001
MAY 23, 1995
N40174 001
JUN 12, 1997
N08107 005
APR 05, 1989
N89628 001
APR 17, 1997
N89915 001
APR 17, 1997

AP
AP
AP

N40078 001
JUN 23, 1995
N40013 001
JUN 23, 1995
N40078 001
JUN 23, 1995

TABLET; ORAL

LEUCOVORIN CALCIUM
PAR PHARM

AB
AB
AB
AB

EQ 5MG BASE
EQ 25MG BASE
EQ 5MG BASE
EQ 25MG BASE

N74544 001
AUG 28, 1997
N74544 002
AUG 28, 1997
N73099 001
MAR 28, 1997
N73101 001
MAR 28, 1997

+
*
LITHIUM CARBONATE
TABLET, EXTENDED RELEASE; ORAL
LITHOBID
SOLVAY
+
CYTOMEL
JONES MEDCL INDS
EQ 0.005MG BASE
EQ 0.025MG BASE
EQ 0.05MG BASE
EQ 0.005MG BASE
EQ 0.025MG BASE
EQ 0.05MG BASE

N10379 001
N10379 002
N10379 003
N10379 001
N10379 002
N10379 003

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3
+ TAP HOLDINGS

LUPRON DEPOT-4
+ TAP HOLDINGS

11.25MG/VIAL
30MG/VIAL

N20708 001
MAR 07, 1997
N20517 002
MAY 30, 1997

INJECTABLE; INJECTION
LORAZEPAM
ABBOTT

AP
AP
AP
AP
AP
AP
AP

N74243 001
APR 12, 1994
N74300 001
APR 12, 1994
N74243 002
APR 12, 1994
N74300 003
MAR 19, 1997
N74243 001
APR 12, 1994
N74300 001
APR 12, 1994

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
ABBOTT

1%

N40013 001
JUN 23, 1995

STERLING WINTHROP
2MG/ML
2MG/ML
4MG/ML
4MG/ML
2MG/ML
2MG/ML

N74243 001
APR 12, 1994
N74300 001
APR 12, 1994
N74243 002
APR 12, 1994
N74300 003
MAR 19, 1997
N74243 001
APR 12, 1994
N74300 001
APR 12, 1994

LORAZEPAM

INJECTABLE; INJECTION

AP LORAZEPAM
STERLING WINTHROP

4MG/ML

N74243 002
APR 12, 1994

SOLUTION; ORAL
LORAZEPAM
+ ROXANE

0.5MG/5ML

N74648 001
MAR 18, 1997

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE
FUJISAWA

500MG/ML

N19316 001
SEP 08, 1986

500MG/ML

N19316 001
SEP 08, 1986

+ MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT

1GM/100ML

N20488 001
JUL 11, 1995

1GM/100ML

N20488 001
JUL 11, 1995

+ MAGNESIUM SULFATE IN PLASTIC CONTAINER
ABBOTT

4GM/100ML

N20309 001
JUN 24, 1994

80MG/ML

N20309 002
JUN 24, 1994

4GM/100ML

N20309 001
JUN 24, 1994

80MG/ML

N20309 002
JUN 24, 1994

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

AA MECLIZINE HCL
KV PHARM

12.5MG
25MG

N85524 001
N85523 001

12.5MG

N85524 001
N85523 001

25MG

12.5MG

N40179 001
JAN 30, 1997

25MG

N40179 002
JAN 30, 1997

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

AA MECLIZINE HCL
ZENITH GOLDLINE

12.5MG
25MG

N84975 001
N84657 001

12.5MG

N83784 001
N83784 001

12.5MG

12.5MG

N84975 001
N84657 001

TABLET; CHEWABLE; ORAL

AA MECLIZINE HCL
ZENITH LABS

25MG

N84976 001
N84976 001

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

AB HUMEGON
ORGANON

75 IU/VIAL; 75 IU/VIAL

N20328 001
SEP 01, 1994

75 IU/VIAL; 75 IU/VIAL

N20328 001
SEP 01, 1994

150 IU/VIAL; 150 IU/VIAL

N20328 002
SEP 01, 1994

150 IU/VIAL; 150 IU/VIAL

N20328 002
SEP 01, 1994

AB REPRONAL
FERRING

75 IU/VIAL; 75 IU/VIAL

N73598 001
JAN 30, 1997

75 IU/VIAL; 75 IU/VIAL

N73598 001
JAN 30, 1997

150 IU/VIAL; 150 IU/VIAL

N73599 001
JAN 30, 1997

150 IU/VIAL; 150 IU/VIAL

N73599 001
JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP MEPERIDINE HCL
MALLINCKRODT

10MG/ML

N40163 001
MAY 12, 1997

TABLET; ORAL
MEPERIDINE HCL
ROXANE

50MG

N40110 001
MAR 12, 1997

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'97 - OCT'97

48

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL
AA ROXANE

100MG

AA ROYCE LABS

50MG

AA

100MG

N40110 002
MAR 12, 1997
N40186 001
JUN 30, 1997
N40186 002
JUN 30, 1997

N20357 002
MAR 03, 1995

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
AA PUREPAC PHARM

200MG

400MG

200MG

400MG

600MG

600MG

AA @ ZENITH GOLDLINE
AA @ ZENITH LABS

N84804 001
N84804 002
N84804 001
N84804 002
N84181 001
N84181 001

POWDER FOR RECONSTITUTION; INHALATION
PROVOCHOLINE
METHAPHARM

100MG/VIAL

ROCHE

100MG/VIAL

N19193 001
OCT 31, 1986
N19193 001
OCT 31, 1986

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB APPLIED ANAL

25MG

AB

50MG

N40011 001
JUL 17, 1997
N40011 002
JUL 17, 1997

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

10MG/5ML

AA JVL

AA MORTON GROVE

10MG/5ML

10MG/5ML

10MG/5ML

@

N74702 001
MAR 24, 1997
N71656 001
OCT 13, 1987
N74702 001
MAR 24, 1997
N71656 001
OCT 13, 1987

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA PUREPAC PHARM

AA

AA

500MG

750MG

500MG

750MG

500MG

750MG

N85718 001
N85718 002
N85718 001
N85718 002
N84648 001
N84648 001
N84648 001
N84648 001
N84648 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

BRISTOL MYERS SQUIBB

500MG

+

850MG

500MG

INJECTABLE; INJECTION

MEXATE-AQ PRESERVED

AP BRISTOL MYERS

AP

N20357 001
MAR 03, 1995

EQ 25MG BASE/ML

N89887 001
APR 14, 1989

METHOTREXATE SODIUM

INJECTABLE; INJECTION

MEXATE-AQ PRESERVED

@ BRISTOL MYERS SQUIBB EQ 25MG BASE/ML

N89887 001
APR 14, 1989METHOXSALEN

CAPSULE; ORAL

OXSORALEN-ULTRA

+ ICN

10MG

N19600 001
OCT 30, 1986CAPSULE, LIQUID FILLED; ORAL
OXSORALEN-ULTRA

* ICN

10MG

N19600 001
OCT 30, 1986METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE
ZENITH GOLDLINEAB2.5MGN87913 001
JUN 03, 1982

@

5MG

N87786 001
MAY 18, 1982

ZENITH LABS

AB2.5MGN87913 001
JUN 03, 1982AB5MGN87786 001
MAY 18, 1982METHYLDOPA

TABLET; ORAL

METHYLDOPA

HALSEY

AB125MGN71751 001
MAR 28, 1988AB250MGN71752 001
MAR 28, 1988

@

125MG

N71751 001
MAR 28, 1988

@

250MG

N71752 001
MAR 28, 1988

PUREPAC PHARM

AB125MGN70749 001
FEB 07, 1986METHYLDOPA

TABLET; ORAL

METHYLDOPA

PUREPAC PHARM

AB250MGN70750 001
FEB 07, 1986AB500MGN70452 001
FEB 07, 1986

@

125MG

N70749 001
FEB 07, 1986

@

250MG

N70750 001
FEB 07, 1986

@

500MG

N70452 001
FEB 07, 1986METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HCL

DANBURY PHARMA

AB5MGN40220 001
AUG 29, 1997AB10MGN40220 002
AUG 29, 1997AB20MGN40220 003
AUG 29, 1997METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN

AB8MG

N11153 004

AB4MGN40232 001
OCT 16, 1997AB4MGN40194 001
OCT 31, 1997AB4MGN40189 001
OCT 31, 1997AB8MGN40189 002
OCT 31, 1997METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

ABBOTT

APEQ 5MG BASE/MLN74147 001
AUG 02, 1996

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
 FAULDING

EQ 5MG BASE/ML

EQ 5MG BASE/ML

EQ 5MG BASE/ML

N71990 001

JAN 18, 1989

N71990 001

JAN 18, 1989

N74147 001

AUG 02, 1996

N20208 001

AUG 17, 1992

N20208 001

AUG 17, 1992

0.75%

0.75%

GEL; VAGINAL
 METROGEL-VAGINAL
 + 3M

* CURATEK

INJECTABLE; INJECTION
METRONIDAZOLE
 STERIS

500MG/100ML

500MG/100ML

N70042 001

DEC 20, 1984

N70042 001

DEC 20, 1984

> ADD >
 > ADD >

SOLUTION; ORAL
METOCLOPRAMIDE
 JVL

EQ 5MG BASE/5ML

N74703 001

OCT 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HCL
 MUTUAL PHARM

EQ 5MG BASE

N71536 002

JAN 16, 1997

METOLAZONE
 TABLET; ORAL
 MYKROX
 MEDEVA

0.5MG

0.5MG

N19532 001

OCT 30, 1987

N19532 001

OCT 30, 1987

N74711 001

FEB 26, 1997

N74711 002

FEB 26, 1997

N74711 003

FEB 26, 1997

150MG

200MG

250MG

METOPROLOL TARTRATE
 INJECTABLE; INJECTION
METOPROLOL TARTRATE
 ABBOTT

1MG/ML

1MG/ML

N74133 001

DEC 21, 1993

N74133 001

DEC 21, 1993

N20689 001

JUN 20, 1997

N20689 002

JUN 20, 1997

EQ 50MG BASE

EQ 100MG BASE

METRONIDAZOLE
 CREAM; TOPICAL
 NORITATE
 + DERMIK LABS

1%

INJECTABLE; INJECTION
 MONISTAT
 * JANSSEN
 @

10MG/ML

10MG/ML

N18040 001

N18040 001

N20743 001

SEP 26, 1997

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'97 - OCT'97

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM
+ J AND J
* JOHNSON RW

2%
2%

N17494 001
N17494 001

LOTION; TOPICAL
MONISTAT-DERM
@ J AND J
@ JOHNSON RW

2%
2%

N17739 001
N17739 001

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL
LEDERLE

*

@

@

EQ 50MG BASE
EQ 100MG BASE
EQ 50MG BASE
EQ 100MG BASE

N50451 003
AUG 10, 1982
N50451 002
AUG 10, 1982
N50451 003
AUG 10, 1982
N50451 002
AUG 10, 1982

MIRTAZAPINE

TABLET; ORAL
REMERN
* ORGANON

30MG
30MG
45MG

N20415 002
JUN 14, 1996
N20415 002
JUN 14, 1996
N20415 003
MAR 17, 1997

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN
@ DUPONT MERCK
@
@
@ ENDO PHARMS
@
@

5MG
10MG
25MG
5MG
10MG
25MG

N17111 001
N17111 002
N17111 003
N17111 001
N17111 002
N17111 003

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL

MOBAN
* DUPONT MERCK
+ ENDO PHARMS

20MG/ML
20MG/ML

N17938 001
N17938 001

TABLET; ORAL

MOBAN
DUPONT MERCK

5MG
10MG
25MG
50MG
100MG
5MG
10MG
25MG
50MG
100MG

N17111 004
N17111 005
N17111 006
N17111 007
N17111 008
N17111 004
N17111 005
N17111 006
N17111 007
N17111 008

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX
+ SCHERING PLOUGH

EQ 0.05MG BASE/SPRAY

N20762 001
OCT 01, 1997

MYCOPHENOLATE MOFETIL

TABLET; ORAL
CELLCEPT
+ SYNTEX

500MG

N50723 001
JUN 19, 1997

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NUBAIN
AP
AP
+ DUPONT MERCK
*

10MG/ML
20MG/ML

N18024 001
N18024 002
MAY 27, 1982

AP
AP
+ ENDO PHARMS
*

10MG/ML
20MG/ML

N18024 001
N18024 002
MAY 27, 1982

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

ABBOTT

0.02MG/ML

N70171 001

SEP 24, 1986

0.4MG/ML

N70172 001

SEP 24, 1986

0.02MG/ML

N70171 001

SEP 24, 1986

0.4MG/ML

N70172 001

SEP 24, 1986

NARCAN

+ DUPONT MERCK

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

ROYCE LABS

EQ 0.5MG BASE;

EQ 50MG BASE

N74736 001

JAN 21, 1997

TALWIN NX

+ SANOFI

EQ 0.5MG BASE;

EQ 50MG BASE

N18733 001

DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

STERIS

50MG/ML

N87598 001

OCT 06, 1983

100MG/ML

N87599 001

OCT 06, 1983

50MG/ML

N87598 001

OCT 06, 1983

100MG/ML

N87599 001

OCT 06, 1983

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

+ FISOXS

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

1.75MG/INH

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN' 97 - OCT' 97

NIACIN

TABLET; ORAL

NIACIN

AA HALSEY

AA @

AA PUREPAC PHARM

AA @

AA @ ZENITH GOLDLINE

AA @ ZENITH LABS

500MG
500MG
500MG
500MG
500MG
500MGN83453 001
N83453 001
N83271 001
N83271 001
N83180 001
N83180 001

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

+ KOS

375MG

+ KOS

500MG

+ KOS

750MG

+ KOS

1GM

NIASPAN TITRATION STARTER PACK

+ KOS 375MG; 500MG; 750MG

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

AB + NOVARTIS

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

AB +

N20076 001

NOV 27, 1991

N20076 002

NOV 27, 1991

N20076 003

NOV 27, 1991

N74645 001

OCT 20, 1997

N74611 001

OCT 20, 1997

N74612 001

OCT 20, 1997

INHALANT; INHALATION

NICOTROL

+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE

N20714 001

MAY 02, 1997

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

@ ZENITH GOLDLINE

@ ZENITH LABS

@ ZENITH LABS

@ ZENITH LABS

50MG
100MG
50MG
100MGN80078 002
N80078 001
N80078 002
N80078 001NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTION

MYLAN

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

N74967 002
JUL 09, 1997N74967 001
JUL 09, 1997N07513 001
N07513 001

EQ 1MG BASE/ML

EQ 1MG BASE/ML

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL

INVAMED

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

N74835 001
JUN 30, 1997N74835 002
JUN 30, 1997N74835 003
JUN 30, 1997N74835 004
JUN 30, 1997N74835 001
JUN 30, 1997N74835 002
JUN 30, 1997N74835 003
JUN 30, 1997N74835 004
JUN 30, 1997NYSTATIN

CREAM; TOPICAL

MYKINAC

@ ALPHARMA

100,000 UNITS/GM

N62387 001
JUL 29, 1982

NYSTATIN

CREAM; TOPICAL

MYKINAC

AT

100,000 UNITS/GM

N62387 001
JUL 29, 1982

ointment; TOPICAL

MYCOSTATIN

AT

100,000 UNITS/GM

N60571 001
N60571 001

@ SQUIBB

100,000 UNITS/GM

N62731 001
SEP 22, 1986

@ WESTWOOD SQUIBB

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

@ ALPHARMA

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

AT

100,000 UNITS/GM

N62731 001
SEP 22, 1986

MYKINAC

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

AT

600MG

* PARKE DAVIS

+ WARNER CHILCOTT

N86742 001
N86742 001

OXYBUTYNYN CHLORIDE

SYRUP; ORAL

AA

5MG/5ML

OXYBUTYNYN CHLORIDE

MORTON GROVE

N74868 001
FEB 12, 1997
N74997 001
OCT 15, 1997

AA

5MG/5ML

OXYBUTYNYN CHLORIDE

NU PHARM

TABLET; ORAL

OXYBUTYNYN CHLORIDE

AB

5MG

VINTAGE PHARMS

N75079 001
OCT 31, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

AT

10MG

* PURDUE FREDERICK

N20553 001
DEC 12, 1995

AT

20MG

* PURDUE FREDERICK

N20553 002
DEC 12, 1995

AT

40MG

* PURDUE FREDERICK

N20553 003
DEC 12, 1995

AT

10MG

+ PURDUE PHARMA

N20553 001
DEC 12, 1995

AT

20MG

+ PURDUE PHARMA

N20553 002
DEC 12, 1995

AT

40MG

OXYMORPHONE HYDROCHLORIDEINJECTABLE; INJECTION

NUMORPHAN
+ DUPONT MERCK
+ + ENDO PHARMS
+ +

1MG/ML
1.5MG/ML
1MG/ML
1.5MG/ML

N11707 002
N11707 001
N11707 002
N11707 001

SUPPOSITORY; RECTAL

NUMORPHAN
+ DUPONT MERCK
+ ENDO PHARMS

5MG
5MG

N11738 004
N11738 004

OXYTOCINSOLUTION; NASAL

SYNTOCINON
+ NOVARTIS
+

40 USP UNITS/ML
40 USP UNITS/ML

N12285 001
N12285 001

PAROMOMYCIN SULFATECAPSULE; ORAL

HUMATIN
+ PARKE DAVIS

EQ 250MG BASE
EQ 250MG BASE
EQ 250MG BASE

N60521 001
N62310 001
N64171 001
JUN 30, 1997

AB
AB
AB

PAROXETINE HYDROCHLORIDESUSPENSION; ORAL

PAXIL
+ SMITHKLINE BEECHAM

EQ 10MG BASE/5ML

N20710 001
JUN 25, 1997

PENICILLIN G POTASSIUMTABLET; ORAL

PENICILLIN G POTASSIUM
+ ZENITH GOLDLINE
ZENITH LABS

400,000 UNITS
400,000 UNITS

N60073 004
N60073 004

AB

PENICILLIN V POTASSIUMTABLET; ORAL

PENICILLIN V POTASSIUM
+ ZENITH GOLDLINE

EQ 125MG BASE
EQ 250MG BASE
EQ 500MG BASE
EQ 125MG BASE
EQ 250MG BASE
EQ 500MG BASE

N11707 002
N11707 001
N11707 002
N11707 001

ZENITH LABS

EQ 125MG BASE
EQ 250MG BASE
EQ 500MG BASE

N11707 002
N11707 001
N11707 002
N11707 001

V-CILLIN K

EQ 125MG BASE
EQ 125MG BASE

N11738 004
N11738 004

PENTAZOCINE LACTATEINJECTABLE; INJECTION

TALWIN
+ ABBOTT
+ SANOFI WINTHROP

EQ 30MG BASE/ML
EQ 30MG BASE/ML

N12285 001
N12285 001

PENTOBARBITAL SODIUMCAPSULE; ORAL

SODIUM PENTOBARBITAL
+ ZENITH GOLDLINE

50MG
100MG
50MG
100MG

N60521 001
N62310 001
N64171 001
JUN 30, 1997

AA
AA

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE
ESI LEDELER

400MG

N20710 001
JUN 25, 1997

AB

MYLAN

400MG

N20710 001
JUN 25, 1997

AB

PUREPAC PHARM

400MG

N20710 001
JUN 25, 1997

AB

TRENTAL

+ HOECHST MARION RSSL

400MG

N20710 001
JUN 25, 1997

AB

TABLET; ORAL

PENICILLIN G POTASSIUM
+ ZENITH GOLDLINE
ZENITH LABS

400,000 UNITS
400,000 UNITS

N60073 004
N60073 004

AB

N60518 001
N60518 002
N60518 003
N60518 001
N60518 002
N60518 003
N60003 001
N60003 001

N16194 001
N16194 001

N83461 001
N83461 002
N83461 001
N83461 002

N74877 001
JUL 08, 1997
N74425 001
JUL 08, 1997
N74878 001
JUL 09, 1997
N18631 001
AUG 30, 1984

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
PHENTERMINE HCL
@ ZENITH LABS

8MG

N85553 001

PINDOLOL

TABLET; ORAL
PINDOLOL
LEMMON

AB

10MG

N74123 002
APR 17, 1997

AB

5MG

N74123 001
APR 17, 1997

PHENYLEUTAZONE

CAPSULE; ORAL
PHENYLEUTAZONE
@ ZENITH GOLDLINE
@ ZENITH LABS

100MG

N88218 001
JUN 24, 1983
N88218 001
JUN 24, 1983

AB

10MG

N74123 002
APR 17, 1997

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
ABBOTT

50MG/ML

N89744 001
DEC 18, 1987
N89744 001
DEC 18, 1987

AP

AP WINTHROP

50MG/ML

PODOFILOX

GEL; TOPICAL
CONDYLOX
+ OCLASSEN

0.5%

N20529 001
MAR 13, 1997

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN
PARKE DAVIS
+

30MG
30MG

N84349 001
N84349 001

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

AT + ALLERGAN

10,000 UNITS/ML;
EQ 1MG BASE/ML

N50567 001
OCT 20, 1988

PIMOZIDE

TABLET; ORAL
ORAP
TEVA

1MG

N17473 003
AUG 27, 1997

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT BAUSCH AND LOMB

10,000 UNITS/ML;
EQ 1MG BASE/ML

N64120 001
FEB 14, 1997

PINDOLOL

TABLET; ORAL
PINDOLOL
LEMMON

5MG

N74123 001
APR 17, 1997

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

AP * ABBOTT
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER
745MG/100ML

N20161 001
NOV 30, 1992

PROMETHAZINE HYDROCHLORIDEINJECTABLE; INJECTIONPROMETHAZINE HCL

<u>AP</u>	<u>STERIS</u>	<u>50MG/ML</u>	<u>N83532 002</u>	<u>AB</u>	<u>40MG</u>	<u>N70518 001</u>
	@	25MG/ML	N83532 001			JUL 07, 1986
<u>AP</u>	<u>STERLING WINTHROP</u>	<u>50MG/ML</u>	<u>N83532 002</u>	<u>AB</u>	<u>60MG</u>	<u>N70519 001</u>
	@	50MG/ML	N83838 002			SEP 24, 1986

TABLET; ORALPROMETHAZINE HCL

<u>BP</u>	<u>ZENITH LABS</u>	<u>12.5MG</u>	<u>N83604 001</u>	<u>AB</u>	<u>90MG</u>	<u>N70520 001</u>
<u>BP</u>	@	25MG	N83603 001			JUL 07, 1986
	@	50MG	N83613 001			SEP 24, 1986
	@	12.5MG	N83604 001			JUL 07, 1986
	@	25MG	N83603 001			N70517 001
	@	50MG	N83613 001			JUL 07, 1986

PROPANTHELINE BROMIDETABLET; ORALPROPANTHELINE BROMIDE

<u>BP</u>	<u>PAR PHARM</u>	<u>15MG</u>	<u>N88377 001</u>	<u>AB</u>	<u>10MG</u>	<u>N70521 001</u>
	@	15MG	DEC 08, 1983			SEP 24, 1986
			N88377 001			N72063 001
			DEC 08, 1983			JUL 29, 1988

PROPOXYPHENE HYDROCHLORIDECAPSULE; ORALPROPOXYPHENE HCL

<u>AA</u>	<u>ROXANE</u>	<u>32MG</u>	<u>N83089 001</u>	<u>AB</u>	<u>80MG</u>	<u>N72069 001</u>
<u>AA</u>	@	65MG	N83089 002			JUL 29, 1988
	@	32MG	N83089 001			N72063 001
	@	65MG	N83089 002			JUL 29, 1988
<u>AA</u>	<u>ZENITH GOLDLINE</u>	<u>32MG</u>	<u>N83597 001</u>	<u>AB</u>	<u>20MG</u>	<u>N72066 001</u>
	@	32MG	N83597 001			JUL 29, 1988
	@	32MG	N83597 001			N72067 001
						JUL 29, 1988

PROPRANOLOL HYDROCHLORIDETABLET; ORALPROPRANOLOL HCL

<u>AB</u>	<u>ROXANE</u>	<u>10MG</u>	<u>N70516 001</u>	<u>AB</u>	<u>10MG</u>	<u>N72069 001</u>
			JUL 07, 1986			JUL 29, 1988
<u>AB</u>		<u>20MG</u>	<u>N70517 001</u>	<u>AB</u>	<u>80MG</u>	<u>N72069 001</u>
			JUL 07, 1986			JUL 29, 1988
						N72068 001
						JUL 29, 1988

PROPRANOLOL HYDROCHLORIDETABLET; ORALPROPRANOLOL HCL

<u>AB</u>	<u>ROXANE</u>	<u>40MG</u>	<u>N83532 002</u>	<u>AB</u>	<u>40MG</u>	<u>N70518 001</u>
			N83532 001			JUL 07, 1986
<u>AB</u>		<u>60MG</u>	<u>N83532 002</u>	<u>AB</u>	<u>60MG</u>	<u>N70519 001</u>
			N83838 002			SEP 24, 1986
<u>AB</u>		<u>80MG</u>		<u>AB</u>	<u>80MG</u>	<u>N70520 001</u>
						JUL 07, 1986
<u>AB</u>		<u>90MG</u>	<u>N83604 001</u>	<u>AB</u>	<u>90MG</u>	<u>N70521 001</u>
			N83603 001			SEP 24, 1986
	@	10MG	N83613 001			N70516 001
	@	20MG	N83604 001			JUL 07, 1986
	@	40MG	N83603 001			N70517 001
	@	60MG	N83613 001			JUL 07, 1986
	@	80MG				N70518 001
	@	10MG				JUL 07, 1986
	@	20MG				SEP 24, 1986
	@	40MG				N70520 001
	@	60MG				JUL 07, 1986
	@	80MG				N70521 001
	@	10MG				SEP 24, 1986
	@	20MG				N72063 001
	@	40MG				JUL 29, 1988
	@	60MG				N72066 001
	@	80MG				JUL 29, 1988
	@	10MG				N72069 001
	@	20MG				JUL 29, 1988
	@	40MG				N72063 001
	@	60MG				JUL 29, 1988
	@	80MG				N72066 001
	@	10MG				JUL 29, 1988
	@	20MG				N72067 001
	@	40MG				JUL 29, 1988
	@	60MG				N72069 001
	@	80MG				JUL 29, 1988
	@	10MG				N72063 001
	@	20MG				JUL 29, 1988
	@	40MG				N72066 001
	@	60MG				JUL 29, 1988
	@	80MG				N72067 001
	@	10MG				JUL 29, 1988
	@	20MG				N72069 001
	@	40MG				JUL 29, 1988
	@	60MG				N72068 001
	@	80MG				JUL 29, 1988

PROPYLTHIOURACIL

TABLET; ORAL
 PROPYLTHIOURACIL
 @ ZENITH GOLDLINE
 @ ZENITH LABS

50MG
 50MG

N80215 001
 N80215 001

EQ 25MG BASE
 EQ 100MG BASE
 EQ 200MG BASE

N20639 001
 SEP 26, 1997
 N20639 002
 SEP 26, 1997
 N20639 003
 SEP 26, 1997

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
 @ ZENITH GOLDLINE

60MG;2.5MG

AA ZENITH LABS

60MG;2.5MG

N85273 001
 DEC 12, 1984
 N85273 001
 DEC 12, 1984

QUINIDINE SULFATE

CAPSULE; ORAL
 CIN-QUIN
 SOLVAY

*
 @
 @

200MG
 300MG
 200MG
 300MG

N85296 001
 N85297 001
 N85296 001
 N85297 001

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

+ ICN
 AP * ROCHE

5MG/ML
 5MG/ML

N09830 001
 N09830 001

SYRUP; ORAL

MESTINON

+ ICN
 * ROCHE

60MG/5ML
 60MG/5ML

N15193 001
 N15193 001

TABLET; ORAL

MESTINON

+ ICN
 * ROCHE

60MG
 60MG

N09829 002
 N09829 002

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+ ICN
 * ROCHE

180MG
 180MG

> DLT >
 > ADD >

AB * ROCHES AH
 AB + WYETH AYERST

300MG
 300MG

N12796 002
 N12796 002

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

STERIS
 @

100MG/ML
 100MG/ML

N83760 001
 N83760 001

> ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >

AB
 AB
 AB
 AB

EQ 150MG BASE

N74655 001
 OCT 22, 1997
 N74655 002
 OCT 22, 1997

ZANTAC 150
 GLAXO WELLCOME

EQ 150MG BASE

N20095 001
 MAR 08, 1994

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANTAC 300
+ GLAXO WELLCOME

EQ 300MG BASE

N20095 002
MAR 08, 1994

TABLET; ORAL

RANITIDINE HCL

BOEHRINGER INGELHEIM

EQ 150MG BASE

N74662 001
AUG 29, 1997

EQ 300MG BASE

N74662 002
AUG 29, 1997

EQ 150MG BASE

N74864 001
OCT 20, 1997

EQ 300MG BASE

N74864 002
OCT 20, 1997

EQ 150MG BASE

N74467 001
AUG 29, 1997

EQ 300MG BASE

N74467 002
AUG 29, 1997

EQ 150MG BASE

N74023 001
AUG 22, 1997

EQ 300MG BASE

N74023 002
AUG 22, 1997

EQ 150MG BASE

N74488 001
JUL 31, 1997

EQ 300MG BASE

N74488 002
JUL 31, 1997

EQ 150MG BASE

N74680 001
SEP 12, 1997

EQ 300MG BASE

N74680 002
SEP 12, 1997

ZANTAC 150
GLAXO WELLCOME

EQ 150MG BASE

N18703 001
JUN 09, 1983

ZANTAC 300
+ GLAXO WELLCOME

EQ 300MG BASE

N18703 002
DEC 09, 1985

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUVAL

+ PAL PAK

100MG

100MG

50MG

N09108 004

N09108 004

N09273 001

RAUWOLFIA SERPENTINA

GLOBAL PHARM

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUWOLFIA SERPENTINA

GLOBAL PHARM

100MG

50MG

100MG

50MG

100MG

50MG

100MG

N09273 002

N09273 001

N09273 002

N11521 001

N11521 002

N11521 001

N11521 002

RESERPINE

TABLET; ORAL

RESERPINE

PUREPAC PHARM

0.1MG

0.25MG

0.1MG

0.25MG

0.25MG

0.25MG

0.1MG

0.25MG

0.1MG

0.25MG

N80753 002

N80753 001

N80753 002

N80753 001

N85207 001

N85207 001

N11185 001

N11185 002

N11185 001

N11185 002

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

EON

300MG

N64150 001

MAY 28, 1997

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

+ SMITHKLINE BEECHAM

EQ 0.25MG BASE

EQ 0.5MG BASE

EQ 1MG BASE

EQ 2MG BASE

N20658 001

SEP 19, 1997

N20658 002

SEP 19, 1997

N20658 003

SEP 19, 1997

N20658 004

SEP 19, 1997

ROPINIROLE HYDROCHLORIDETABLET; ORAL
REQUIP

+ SMITHKLINE BEECHAM EQ 5MG BASE

N20658 005
SEP 19, 1997SALMETEROL XINAFOATEPOWDER; INHALATION
SEREVENT

+ GLAXO WELLCOME EQ 0.046MG BASE/INH

N20692 001
SEP 19, 1997SAMARIUM SM 153 LEXIDRONAM PENTASODIUMINJECTABLE; INJECTION
QUADRAMET
CYTOGEN

50mCi/ML

N20570 001
MAR 28, 1997SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

@ ZENITH GOLDLINE

@ ZENITH LABS

SODIUM SECOBARBITAL

HALSEY

@

100MG

100MG

100MG

100MG

N85869 001

N85869 001

N84676 001

N84676 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

+ SOMERSET

5MG

5MG

N20647 001

MAY 15, 1996

N20647 001

MAY 15, 1996

TABLET; ORAL

SELEGILINE HCL

APOTEX

5MG

N74871 001

JUN 06, 1997

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HCL

APOTHECON

5MG

N74672 001

APR 01, 1997

ENDO LABS

5MG

N74585 001

AUG 02, 1996

ENDO PHARMS

5MG

N74565 001

AUG 02, 1996

TEVA

5MG

N74744 001

JAN 27, 1997

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+ SERONO

EQ 0.5MG BASE/VIAL

N20443 001

SEP 26, 1997

+

EQ 1MG BASE/VIAL

N20443 002

SEP 26, 1997

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

9MG/ML

ABBOTT

AP

N19465 002

JUL 15, 1985

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

GOLDEN PHARMS

100 uCi

N18671 001

MAY 27, 1982

200 uCi

N18671 002

MAY 27, 1982

400 uCi

N18671 003

MAY 27, 1982

SYNCOR PHARMS

100 uCi

N18671 001

MAY 27, 1982

200 uCi

N18671 002

MAY 27, 1982

400 uCi

N18671 003

MAY 27, 1982

SODIUM IODIDE, I-131CAPSULE; ORAL
IODOTOPE
BRACCO8-100 uCi
1-50mCi
8-100 uCi
1-130mCiN10929 001
N10929 003
N10929 001
N10929 003N73199 001
SEP 11, 1992
N73199 001
SEP 11, 1992SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
NITROPRESS
ABBOTT50MG/VIAL
50MG/VIALN71555 001
NOV 16, 1987
N71555 001
NOV 16, 1987N87770 001
NOV 19, 1982
N87770 001
NOV 19, 1982SOMATROPIN, BIOSYNTHETICINJECTABLE; INJECTION
NORDITROPIN
BX + NOVO NORDISK

4MG/VIAL

N19721 001
MAY 08, 1995N87769 001
JUN 01, 1982
N87769 001
JUN 01, 1982SEROSTIM
SERONO

4MG/VIAL

N20604 003
JUL 25, 1997SPIRONOLACTONETABLET; ORAL
SPIRONOLACTONE
@ ZENITH GOLDLINE
ZENITH LABS25MG
25MGN87108 001
N87108 001N80087 001
N80087 001
N80142 001
N80142 001SULFAMETHOXAZOLESUSPENSION; ORAL
GANTANOL
* ROCHE
@500MG/5ML
500MG/5MLN13664 002
N13664 002N07757 002
N07757 002SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM
ABBOTT

80MG/ML; 16MG/ML

AP
STERLING WINTHROP

80MG/ML; 16MG/ML

N73199 001
SEP 11, 1992
N73199 001
SEP 11, 1992SULFINPYRAZONECAPSULE; ORAL
SULFINPYRAZONE

200MG

AB
ZENITH GOLDLINEN87770 001
NOV 19, 1982
N87770 001
NOV 19, 1982

200MG

AB
ZENITH LABS

TABLET; ORAL

SULFINPYRAZONE
@ ZENITH GOLDLINE

100MG

AB
ZENITH LABSN87769 001
JUN 01, 1982
N87769 001
JUN 01, 1982

100MG

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE
PUREPAC PHARM

500MG

AB
@N80087 001
N80087 001
N80142 001
N80142 001AB + ZENITH GOLDLINE
AB * ZENITH LABS500MG
500MG
500MGSOLUTION/DROPS; OPHTHALMIC

GANTRISIN

* ROCHE

EQ 4% BASE

EQ 4% BASE

SUMATRIPTAN

SPRAY; NASAL					
IMITREX					
+ GLAXO WELLCOME	5MG/SPRAY				N18107 001
+	10MG/SPRAY	N20626 001			
		AUG 26, 1997			
+	20MG/SPRAY	N20626 002			
		AUG 26, 1997			
		N20626 003			
		AUG 26, 1997			

TAMOXIFEN CITRATE

TABLET; ORAL					
NOLVADEX					
+ ZENECA	EQ 10MG BASE	N17970 001			
	EQ 10MG BASE	N17970 001			

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL					
FLOMAX					
+ BOEHRINGER INGELHEIM	0.4MG	N20579 001			
		APR 15, 1997			

TAZAROTENE

GEL; TOPICAL					
TAZORAC					
ALLERGAN	0.05%	N20600 001			
		JUN 13, 1997			
+	0.1%	N20600 002			
		JUN 13, 1997			

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION					
AM-MAA					
@ CIS					
ES					

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION					
MDP-BRACCO					
AP					

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION					
MIRALUMA					
DUPONT					

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL					
LAMISIL					
+ NOVARTIS					

TERFENADINE

TABLET; ORAL					
SELDANE					
AB + HOECHST MARION RSSL	60MG	N18949 001			
		MAY 08, 1985			
TERFENADINE					
AB BAKER NORTON	60MG	N74475 001			
		JAN 03, 1997			

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL					
ANDRODERM					
+ THERATECH					

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL					
TETRACYCLINE HCL					
AB WARNER CHILCOTT	250MG	N62300 001			

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL

AB WARNER CHILCOTT 500MG
 @ 250MG
 @ 500MG

INJECTABLE; INJECTION

ACHROMYCIN* LEDERLE

AP 250MG/VIAL
 AP 500MG/VIAL
 AP 250MG/VIAL
 + 500MG/VIAL

TETRACINPFIZER

AP 250MG/VIAL
 AP 500MG/VIAL
 @ 250MG/VIAL
 @ 500MG/VIAL

SUSPENSION; ORAL

TETRACYCLINE HCLALPHARMA

AB 125MG/5ML
 @ 125MG/5ML
 AB 125MG/5ML
 @ 125MG/5ML

TETRACINPFIPHARMECS

AB 125MG/5ML
 @ 125MG/5ML

TETRAMEDZENITH GOLDLINE

AB 125MG/5ML
 @ 125MG/5ML
 @ 125MG/5ML

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201DUPONT

AP 1mCi/ML
 AP 1mCi/ML

+ MALLINCKRODT

AP 1mCi/ML
 AP 1mCi/ML

+ MEDI PHYSICS

AP 1mCi/ML
 AP 1mCi/ML

FEB 27, 1996
 FEB 27, 1996

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

BP 100MG
 BP 200MG
 @ 100MG
 @ 200MG

THEOPHYLLINEKV PHARM

BP 100MG
 BP 200MG
 @ 100MG
 @ 200MG

CAPSULE, EXTENDED RELEASE; ORAL

SOMOPHYLLIN-CRTGRAHAM DM

BC 50MG
 BC 100MG
 BC 200MG

BC 250MG
 BC 300MG

@

@ 50MG

@ 100MG

@ 200MG

@ 250MG

@ 300MG

THEO-DURKEY PHARMS

BC 50MG

BC 75MG

BC 125MG

BC 200MG

@ 50MG

@ 75MG

@ 125MG

@ 200MG

@ 50MG

@ 75MG

@ 125MG

@ 200MG

N85264 001
 N85264 002
 N85264 001
 N85264 002

N85263 001
 N85263 002
 N85263 001
 N85263 002

N87763 001
 FEB 27, 1985
 N87194 001
 N88382 001

FEB 27, 1985
 N87193 001
 N88383 001
 FEB 27, 1985

N87763 001
 FEB 27, 1985
 N87194 001
 N88382 001

FEB 27, 1985
 N87193 001
 N88383 001
 FEB 27, 1985

N88022 001
 SEP 10, 1985
 N88015 001
 SEP 10, 1985

SEP 10, 1985
 N88016 001
 SEP 10, 1985
 N87995 001

SEP 10, 1985
 N88022 001
 SEP 10, 1985
 N88015 001

SEP 10, 1985
 N88016 001
 SEP 10, 1985
 N87995 001

SEP 10, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

AP ABBOTT

100MG/ML

N40079 001

MAY 03, 1996

AP SANOFI WINTHROP

100MG/ML

N40079 001

MAY 03, 1996

AP STERIS

100MG/ML

N83534 001

200MG/ML

N83534 002

100MG/ML

N83534 001

200MG/ML

N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HCL

AA PHARM ASSOC

30MG/ML

N40187 001

AUG 28, 1997

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

* ARMOUR PHARM

@ RHONE POULENC

10 IU/VIAL

N08682 001

N08682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

ABBOTT

4MG

N20646 001

SEP 30, 1997

12MG

N20646 002

SEP 30, 1997

16MG

N20646 003

SEP 30, 1997

20MG

N20646 004

+

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+ SANOFI

EQ 200MG BASE

N20707 001

MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

* LEBRAS

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

N20439 001

MAR 31, 1995

N20439 002

MAR 31, 1995

N20439 001

MAR 31, 1995

N20439 002

MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

ADV REMEDIES

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

EQ 0.25% BASE

EQ 0.5% BASE

N74465 001

MAR 25, 1997

N74466 001

MAR 25, 1997

N74515 001

MAR 25, 1997

N74516 001

MAR 25, 1997

N74778 001

MAR 25, 1997

N74776 001

MAR 25, 1997

N74667 001

MAR 25, 1997

N74668 001

MAR 25, 1997

N74746 001

MAR 25, 1997

N74747 001

MAR 25, 1997

TIOCONAZOLE

OINTMENT; VAGINAL

VAGISTAT-1

* BRISTOL MYERS

EQ 0.5%

N19355 001

DEC 30, 1986

TIOPRONIN

TABLET; ORAL
TIOPRONIN
+ MISSION PHARMA
* UNIV TX

100MG
100MG

N19569 001
AUG 11, 1988
N19569 001
AUG 11, 1988

AB TRAZODONE HCL
TEVA

150MG

N74357 001
APR 30, 1997

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE
PUREPAC PHARM

AB 500MG
@
500MG

N88950 001
JUN 17, 1985
N88950 001
JUN 17, 1985

AB 0.025%
AVITA
PENEDERM

N20404 003
JAN 14, 1997

AB 0.025%
RETIN-A
+ J AND J

N19049 001
SEP 16, 1988

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM
BAKER NORTON

AB EQ 600MG BASE
AB EQ 600MG BASE
EQ 600MG BASE
EQ 600MG BASE

N74399 001
MAR 28, 1996
N74729 001
FEB 27, 1997
N74729 001
FEB 27, 1997
N74399 001
MAR 28, 1996

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE
PUREPAC PHARM

BP 2MG
BP 4MG
BP 2MG
BP 4MG

N84020 002
N84020 003
N84020 002
N84020 003
N83750 001
N83750 001

@
@
@ ZENITH GOLDLINE
ZENITH LABS

N20475 001
FEB 07, 1997

TOPIRAMATE

TABLET; ORAL
TOPAMAX
@ JOHNSON RW

400MG

N20505 006
DEC 24, 1996

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON
+ ORION

EQ 60MG BASE

N20497 001
MAY 29, 1997

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE
ALPHARMA

AT 0.1%
@

N87192 001
SEP 08, 1982
N87192 001
SEP 08, 1982

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
 VANCOCIN HCL IN PLASTIC CONTAINER
 + BAXTER HLTHCARE EQ 500MG BASE/100ML
 + LILLY EQ 500MG BASE/100ML
 VANCOLED
 LEDERLE EQ 500MG BASE/VIAL
 + AP EQ 500MG BASE/VIAL
 + AP EQ 1GM BASE/VIAL
 + AP EQ 1GM BASE/VIAL
 + AP EQ 10GM BASE/VIAL
 + AP EQ 10GM BASE/VIAL
 + AP EQ 10GM BASE/VIAL
 + AP

N50671 001
 APR 29, 1993
 N50671 001
 APR 29, 1993
 N62682 001
 JUL 22, 1986
 N62682 001
 JUL 22, 1986
 N62682 002
 MAR 30, 1988
 N62682 002
 MAR 30, 1988
 N62682 005
 MAY 11, 1988
 N62682 005
 MAY 11, 1988

> DLT >
 > DLT >
 > ADD >
 > ADD >
 > DLT >
 > DLT >
 > ADD >
 > ADD >
 > DLT >
 > ADD >
 > ADD >

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 VERAPAMIL HCL
 BAKER NORTON 180MG
 AB 180MG
 > DLT >
 > DLT >
 AB 120MG
 MYLAN 120MG
 AB 120MG
 AB 180MG
 ZENITH GOLDLINE 120MG
 AB 120MG
 AB 180MG
 AB 180MG
 AB 240MG
 AB 240MG
 AB 240MG
 AB 240MG

N74330 001
 JAN 31, 1994
 N73568 001
 JUL 31, 1992
 N74587 002
 FEB 21, 1997
 N74587 003
 SEP 09, 1997
 N73568 002
 OCT 10, 1997
 N74330 001
 JAN 31, 1994
 N73568 001
 JUL 31, 1992

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCERX
 AP * BRISTOL MYERS 5MG/VIAL
 @ BRISTOL MYERS SQUIBB 5MG/VIAL
 VINCRISTINE SULFATE
 FAULDING 5MG/VIAL
 + 5MG/VIAL
 VITAMIN A PALMITATE

N20699 001
 OCT 20, 1997
 N20699 002
 OCT 20, 1997
 N20699 003
 OCT 20, 1997
 N20699 004
 OCT 20, 1997

CAPSULE, EXTENDED RELEASE; ORAL
 EFFEXOR XR EQ 37.5MG BASE
 + WYETH AYERST EQ 75MG BASE
 + EQ 100MG BASE
 + EQ 150MG BASE

> ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 EFFEXOR XR
 + WYETH AYERST EQ 37.5MG BASE
 + EQ 75MG BASE
 + EQ 100MG BASE
 + EQ 150MG BASE
 VERAPAMIL HYDROCHLORIDE
 INJECTABLE; INJECTION
 VERAPAMIL HCL
 ABBOTT 2.5MG/ML
 STERLING WINTHROP 2.5MG/ML

N70577 001
 FEB 02, 1987
 N70577 001
 FEB 02, 1987

EQ 50,000 UNITS BASE
 EQ 50,000 UNITS BASE
 EQ 50,000 UNITS BASE
 EQ 50,000 UNITS BASE

N83035 001
 N83190 001
 N83035 001
 N83190 001

TABLET, EXTENDED RELEASE; ORAL
 ISOPTIN SR
 AB + KNOLL PHARM 120MG

N19152 003
 MAR 06, 1991

WARFARIN SODIUM

TABLET; ORAL
COUMADIN
 DUPONT MERCK

AB	1MG	N09218 022
AB	2MG	MAR 01, 1990
AB	2.5MG	N09218 013
AB	4MG	N09218 018
AB	5MG	N09218 023
AB	7.5MG	AUG 24, 1993
AB	10MG	N09218 007
AB		N09218 016
AB		N09218 005
AB	1MG	N40145 001
AB	2MG	MAR 26, 1997
AB	2.5MG	N40145 002
AB	4MG	MAR 26, 1997
AB	5MG	N40145 003
AB	7.5MG	MAR 26, 1997
AB	10MG	N40145 004
AB		MAR 26, 1997
AB		N40145 005
AB		MAR 26, 1997
AB		N40145 006
AB		MAR 26, 1997
AB		N40145 007
AB		MAR 26, 1997
AB		N40196 001
AB		SEP 30, 1997
AB		N40196 002
AB		SEP 30, 1997
AB		N40196 003
AB		SEP 30, 1997
AB		N40196 004
AB		SEP 30, 1997
AB		N40196 005
AB		SEP 30, 1997
AB		N40196 006
AB		SEP 30, 1997
AB		N40196 007
AB		SEP 30, 1997

+
WARFARIN SODIUM
 BARR

ZINC ACETATE

CAPSULE; ORAL
GALZIN
 + TEVA

EQ 50MG ZINC

N20458 002
 JAN 28, 1997

ZINC ACETATE

CAPSULE; ORAL
GALZIN
 TEVA

EQ 25MG ZINC

N20458 001
 JAN 28, 1997

IBUPROFEN

TABLET; ORAL

NUPRIN

® PHARMACIA AND UPJOHN 200MG

N19012 003
JUL 29, 1987

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

VELOSULIN BR HUMAN

+ NOVO NORDISK

100 UNITS/ML

N19450 001
MAY 30, 1986

VELOSULIN HUMAN

+ NOVO NORDISK

100 UNITS/ML

N19450 001
MAY 30, 1986

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

J AND J

1%

> ADD >
> ADD >
> ADD >

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HCL

MORTON GROVE

1MG/5ML

N74730 001
AUG 28, 1997

TABLET, CHEWABLE; ORAL

IMODIUM A-D

+ MCNEIL

2MG

N20448 001
JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

IMODIUM ADVANCED

+ MCNEIL

2MG; 125MG

N20606 001
JUN 26, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

PERRIGO

2%

N74760 001
MAY 15, 1997
N74444 001
JAN 13, 1997

TARO

2%

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ALPHARMA

2%, 100MG

N74586 001
JUL 17, 1997

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

G AND W LABS

100MG

N74414 001
APR 30, 1997
N74395 001
MAR 20, 1997

+ PERRIGO

100MG

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

MORTON GROVE

2%

N74767 001
FEB 28, 1997

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

GRANULEC

EQ 200MG BASE

N74635 001
JAN 13, 1997

INVAMED

EQ 200MG BASE

N74646 001
JAN 13, 1997

NOVOPHARM

EQ 200MG BASE

N74635 001
JAN 13, 1997

PERRIGO

EQ 200MG BASE

N74661 001
JAN 13, 1997

PVT FORM

EQ 200MG BASE

N74789 001
FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL

NIX

+ WARNER LAMBERT 1%

N19918 001

MAY 02, 1990

+ WARNER WELLCOME 1%

N19918 001

MAY 02, 1990

PSEUDOPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG

N71798 001

MAR 16, 1989

N71798 001

MAR 16, 1989

@

120MG;5MG

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%;0.3%

N20231 001

JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL

VAGISTAT-1

+ BRISTOL MYERS SQUIBB 6.5%

N20676 001

FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 10/ OCTOBER '97

NO OCTOBER 1997 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Star, Robert A., M.D. UT-Southwestern Medical School 5323 Harry Hines Dallas, TX 75235 DD=08/19/1997

Orphan Product Designations and Approvals List

January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
Apomorphine TN= Zydis	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon Wiltshire UK SN5 8RU, DD=10/20/1997
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997

Orphan Product Designations and Approvals List

January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Busulfan TN=	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997
CAMPATH-1H TN=	Treatment of chronic lymphocytic leukemia.	L&I Partners, LP 11550 IH 10 West, Suite 300 San Antonio, TX 78230 DD=10/20/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg, MD 20877 DD=08/19/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997

Orphan Product Designations and Approvals List January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Diazepam viscous solution for rectal administration TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco, CA 94080 DD=02/25/1992 MA=07/29/1997
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Street Suite 8J New York, NY 10019 DD=06/02/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997

Orphan Product Designations and Approvals List January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997

Orphan Product Designations and Approvals List January 1997 through October 1997

Name	Indication Designated	Sponsor & Address
Generic Name		DD= Date Designated
TN=Trade Name		MA=Marketing Approval
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997 MA=08/04/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Pegylated recombinant human megakaryocyte growth and development factor TN= MEGAGEN	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=10/20/1997
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross, GA 30092 DD=08/05/1997

Orphan Product Designations and Approvals List

January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Purified extract of Pseudomonas aeruginosa TN= ImmuDyn	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street Cambridge, MA 02139 DD=09/22/1997
RGG0853, E1A lipid complex TN=	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive way, Suite 100 Seattle, WA 98101 DD=10/27/1997

Orphan Product Designations and Approvals List January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human acid alpha-glucosidas e TN=	Treatment of glycogen storage disease type II.	Chen, Y.T., M.D., Ph.D. Department of Pediatrics Duke University Medical Center Durham, NC 27710 DD=08/19/1997
Recombinant human alpha-L-iduronid ase TN=	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceuticals, Inc. 11 Pimental Court Novato, CA 94949 DD=09/24/1997
Recombinant human interleukin-12 TN=	Treatment of renal cell carcinoma.	Genetics Institute 87 CambridgePark Drive Cambridge, MA 02140 DD=10/20/1997
Recombinant human thrombopoietin TN=	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=09/29/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Sermorelin acetate TN= Geref	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=09/14/1988 MA=09/26/1997
Short chain fatty acid enema TN= Colomed	Treatment of chronic radiation proctitis.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=08/19/1997

Orphan Product Designations and Approvals List January 1997 through October 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Testosterone TN= TheraDerm Testosterone Transdermal System	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	TheraTech, Inc. 417 Wakara Way Salt Lake City, UT 84108 DD=09/22/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

- D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34 EVERY FOUR MONTHS DOSAGE REGIMEN

NEW INDICATION

- I-177 TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
- I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
- I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
- I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
- I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
- I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
- I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
- I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
- I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
- I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
- I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
- I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
- I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
- I-192 THE PREVENTION OF DEEP VEINTHROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
- I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
- I-194 CONGESTIVE HEART FAILURE
- I-195 USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS
NEW INDICATION

I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
 I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
 I-198 USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF
 HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OF A
 ONE-YEAR HISTORY OF A DUODENAL ULCER
 I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF
 TYPE II DIABETES
 I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
 I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
 I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
 I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
 I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF
 THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
 I-205 INITIAL ANTICONSULSANT TREATMENT OF STATUS EPILEPTICUS
 I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
 I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN
 IMMUNOCOMPETENT ADULTS
 I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION

PATENT USE CODE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
 U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM
 HYPERCHOLESTEROLEMIA
 U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR
 DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
 U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-
 DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
 U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
 U-166 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
 U-167 METHOD FOR TREATING HIV-1 INFECTION
 U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF
 ACTION IN THE TREATMENT OF ASTHMA
 U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC
 RESONANCE IMAGING
 U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST
 AGENT
 U-171 METHODS OF USING THE COMPOUND/DRUGPRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC
 RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
 U-172 TREATMENT OF GENITAL WARTS
 U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
 U-174 USE AS AN ANTIHISTAMINE AGENT
 U-175 METHOD OF TREATING MALIGNANT TUMORS
 U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING
 SPECIFIC PSYCHOSIS
 U-177 FUNGICIDE

PATENT AND EXCLUSIVITY TERMS
PATENT USE CODE

- U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
- U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
- U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
- U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
- U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
- U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
- U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
- U-185 METHOD OF TREATING HYPERTENSION
- U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
- U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
- U-188 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
- U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
- U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
- U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
- U-192 USE IN TREATING ALLERGIC REACTIONS
- U-193 PSORIASIS
- U-194 TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
- U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
- U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
- U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
- U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
- U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
- U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-205 METHOD OF TREATING HEARTBURN
- U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION
- U-207 USE AS NASAL SPRAY
- U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
- U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020059 001	ADENOSINE; ADENOSCAN	5070877	MAY 18, 2009	U-116	NC	OCT 24, 1999
020291 001	ALBUTEROL SULFATE; COMBIVENT	5603918	JUN 09, 2015		NP	AUG 15, 1999
020503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	5225183	JUL 06, 2010			
		5439670	JUL 06, 2010			
		5605674	FEB 25, 2014			
020560 001	ALENDRONATE SODIUM; FOSAMAX	4621077	AUG 06, 2007	U-114	1-185	APR 25, 2000
		5681590	DEC 02, 2012		1-187	APR 25, 2000
020560 002	ALENDRONATE SODIUM; FOSAMAX	4621077	AUG 06, 2007	U-114	1-185	APR 25, 2000
		5681590	DEC 02, 2012		1-187	APR 25, 2000
020560 003	ALENDRONATE SODIUM; FOSAMAX	4621077	AUG 06, 2007	U-114	NS	APR 25, 2000
		5681590	DEC 02, 2012		1-185	APR 25, 2000
		5358941	DEC 02, 2012		1-187	APR 25, 2000
					NCE	SEP 29, 2000
020649 001	ALPROSTADIL; EDEX				NP	JUL 06, 1998
020649 002	ALPROSTADIL; EDEX				NP	JUL 06, 1988
020649 003	ALPROSTADIL; EDEX				NP	JUL 06, 1998
020649 004	ALPROSTADIL; EDEX				NP	JUL 06, 1998
020221 001	AMIFOSTINE; ETHYOL				NP	JUL 06, 1998
020333 001	ANAGRELIDE HYDROCHLORIDE; AGRYLIN	5424471	JUL 31, 2012			
		5591731	JUL 31, 2012			
020333 002	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
					ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020541 001	ANASTROZOLE; ARIMIDEX	4935437	DEC 27, 2009		NCE	SEP 12, 2002
020541 001	ANASTROZOLE; ARIMIDEX	4935437	JUN 10, 2008		NCE	MAY 23, 2002
020420 001	ARBUTAMINE HYDROCHLORIDE; GENESA				NCE	DEC 17, 2001
020227 002	ARDEPARIN SODIUM; NORMIFLO					
020702 001	ATORVASTATIN CALCIUM; LIPITOR	4681893	MAY 30, 2006	U-161		
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
020702 002	ATORVASTATIN CALCIUM; LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
020702 003	ATORVASTATIN CALCIUM; LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5164194	NOV 17, 2009	U-207		
020114 001	AZELASTINE HYDROCHLORIDE; ASTELIN				NP	DEC 24, 1999
020486 001	BECLOMETHASONE DIPROPIONATE; VANCERIL DOUBLE STRENGTH	4397839	JUL 01, 2005			
020032 001	BERACTANT; SURVANTA	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
020619 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC PILO	4636505	OCT 01, 2008			
020498 001	BICALUTAMIDE; CASODEX	4472382	SEP 18, 2001	U-197		
		5389613	SEP 18, 2001	U-197		
020490 001	BRIMONIDINE TARTRATE; ALPHAGAN				NP	MAR 13, 2000
					NCE	SEP 06, 2001
					NCE	JUL 15, 2002
020535 002	BROMFENAC SODIUM; DURACT	4907583	MAR 13, 2007			
020441 002	BUDESONIDE; PULMICORT	4524769	JUN 25, 2002			
		4668218	APR 11, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020441 003	BUDESONIDE; PULMICORT	4907583 4524769 4668218 5358970 5358970 5358970 5358970 5427798 RE33994 5358970 5427798 RE33994 4215104 4258027 4215104 4258027 5021458 4078071 4526892 4866048	MAR 13, 2007 JUN 25, 2002 APR 11, 2006 AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 18, 2004 AUG 12, 2013 AUG 12, 2013 AUG 18, 2004 MAR 26, 1999 MAR 26, 1999 MAR 26, 1999 JUN 04, 2008 MAR 07, 1997 JUL 02, 2002 DEC 29, 2007	U-177		FEB 07, 2000 DEC 23, 2001 MAR 20, 2000 DEC 29, 1998 DEC 29, 1998 MAR 03, 2000
		4866048	SEP 12, 2006		NDF	
		4657927 4657927 4657927	APR 14, 2004 APR 14, 2004 APR 14, 2004	U-175 U-175 U-175		
		4503067	MAR 05, 2002	U-3	I-194 I-194 I-194 NCE NCE	MAY 29, 2000 MAY 29, 2000 MAY 29, 2000 SEP 14, 2000 JUN 26, 2002
		5006530 5177080 5006530 5177080 5006530 5177080 5006530 5177080 4525358 4525358	JAN 17, 2009 NOV 26, 2011 JAN 17, 2009 NOV 26, 2011 JAN 17, 2009 NOV 26, 2011 JAN 17, 2009 NOV 26, 2011 JUN 25, 2007 JUN 25, 2007		NCE NCE NCE NCE	JUN 26, 2002 JUN 26, 2002 JUN 26, 2002 JUN 26, 2002
		5286754 4670444	FEB 15, 2011 DEC 09, 2003	U-36	NDF I-188	JUL 21, 2000 JUN 03, 2000
		4705789	NOV 10, 2004		I-188 I-188 I-188 I-179 I-201	JUN 03, 2000 JUN 03, 2000 JUN 03, 2000 OCT 21, 1999 AUG 07, 2000

>ADD>
>ADD>
>ADD>
>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-201	AUG 07, 2000
017533 001	CLONAZEPAM; KILONOPIN				I-179	OCT 21, 1999
017533 002	CLONAZEPAM; KILONOPIN				I-179	AUG 07, 2000
017533 003	CLONAZEPAM; KILONOPIN				I-179	OCT 21, 1999
017533 005	CLONAZEPAM; KILONOPIN				I-184	APR 09, 2000
017533 006	CLONAZEPAM; KILONOPIN				I-184	APR 09, 2000
020463 001	CROMOLYN SODIUM; NASALCROM				I-184	APR 09, 2000
020430 001	DANAPAROID SODIUM; ORGARAN				I-184	APR 09, 2000
020705 001	DELAVIRDINE MESYLATE; RESCRIPTOR				I-184	APR 09, 2000
017922 001	DESMOPRESSIN ACETATE; DDAVP				NP	JAN 03, 2000
017922 002	DESMOPRESSIN ACETATE; DDAVP	5164377	OCT 03, 2010		NCE	APR 04, 2002
		5563142	OCT 08, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
		5500413	JUN 29, 2013			
		5500413	JUN 29, 2013			
		5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5462740	OCT 31, 2012		NDF	JUL 29, 2000
017922 003	DESMOPRESSIN ACETATE; DDAVP	5462740	OCT 31, 2012		ODE	JUL 29, 2004
018938 001	DESMOPRESSIN ACETATE; DDAVP				NDF	JUL 29, 2000
018938 002	DESMOPRESSIN ACETATE; DDAVP				ODE	JUL 29, 2004
019955 001	DESMOPRESSIN ACETATE; DDAVP				ODE	JUL 29, 2004
019955 002	DESMOPRESSIN ACETATE; DDAVP				NDF	JUL 29, 2000
020648 001	DIAZEPAM; DIASTAT				ODE	JUL 29, 2004
020648 002	DIAZEPAM; DIASTAT				ODE	JUL 29, 2004
020648 003	DIAZEPAM; DIASTAT				NDF	JUL 29, 2000
020648 004	DIAZEPAM; DIASTAT				ODE	JUL 29, 2004
020648 005	DIAZEPAM; DIASTAT				NDF	JUL 29, 2000
020037 001	DICLOFENAC SODIUM; VOLTAREN	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020154 002	DIDANOSINE; VIDEX	4960799	OCT 03, 2007			
020154 003	DIDANOSINE; VIDEX	4829088	APR 14, 2007			
020154 004	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020154 005	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020155 004	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020155 005	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020156 001	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
018723 001	DIVALPROEX SODIUM; DEPAKOTE	5616566	AUG 29, 2006	U-180		
					I-181	JUN 20, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020378 002	FOLLITROPIN ALFA/BETA; GONAL-F					
020235 001	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-86	NP	SEP 29, 2000
020235 002	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-86		
020235 003	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008			
020622 001	GLATIRAMER ACETATE; COPAXONE	4087544	JAN 16, 2000	U-86		
020329 001	GLIPIZIDE; GLUCOTROL XL	5591454	JAN 07, 2014	U-150	00E	DEC 20, 2003
020329 002	GLIPIZIDE; GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
019726 001	GOSERELIN ACETATE; ZOLADEX					
020758 001	HYDROCHLOROTHIAZIDE; IRBESARTAN-HYDROCHLOROTHIAZID	5270317	MAR 20, 2011		I-191	JUN 27, 2000
020758 002	HYDROCHLOROTHIAZIDE; IRBESARTAN-HYDROCHLOROTHIAZID	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020504 001	HYDROCHLOROTHIAZIDE; MICROZIDE	4344949	OCT 03, 2000		NCE	SEP 30, 2002
020729 001	HYDROCHLOROTHIAZIDE; UNIRETIC	4743450	FEB 24, 2007		NS	DEC 27, 1999
020729 002	HYDROCHLOROTHIAZIDE; UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
020729 002	HYDROCHLOROTHIAZIDE; UNIRETIC	4743450	FEB 24, 2007		NC	JUN 27, 2000
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN				NC	SEP 23, 2000
020267 002	IBUPROFEN; JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
020723 001	IMIQUIMOD; ALDARA				NCE	FEB 27, 2002
020808 001	IOUXANOL; VISIPAQUE 270	4689338	AUG 25, 2004	U-172		
		5238944	AUG 24, 2010			
		5349085	SEP 20, 2011			
		4278654	JUL 03, 1999			
		4396597	JUL 03, 1999			
		5349085	SEP 20, 2011			
		4278654	JUL 03, 1999			
		4396597	JUL 03, 1999			
		5270317	MAR 20, 2011			
		5270317	MAR 20, 2011			
		5270317	MAR 20, 2011			
		5624668	SEP 29, 2015			
020808 002	IOUXANOL; VISIPAQUE 320					
020757 001	IRBESARTAN; AVAPRO				NCE	SEP 30, 2002
020757 002	IRBESARTAN; AVAPRO				NCE	SEP 30, 2002
020757 003	IRBESARTAN; AVAPRO				NCE	SEP 30, 2002
040024 001	IRON DEXTRAN; DEXFERRUM					
020083 001	ITRACONAZOLE; SPORANOX					
020657 001	ITRACONAZOLE; SPORANOX					
019927 001	KETOCONAZOLE; NIZORAL					
020310 001	KETOCONAZOLE; NIZORAL					
020857 001	LAMIVUDINE; COMBIVIR					
020406 001	LANSOPRAZOLE; PREVACID					
020406 002	LANSOPRAZOLE; PREVACID					
020726 001	LETROZOLE; FEMARA					
019732 001	LEUPROLIDE ACETATE; LUPRON DEPOT					
		4978672	DEC 18, 2007	U-203	I-178	DEC 06, 1999
		5631020	MAY 20, 2014		NDF	FEB 21, 2000
		5631021	MAY 20, 2014		I-186	MAY 30, 2000
		4954298	NOV 01, 2004		NP	OCT 10, 2000
		5480656	JAN 02, 2013		NCE	NOV 17, 2000
		5643607	JUL 01, 2014		I-195	JUN 17, 2000
					I-196	MAY 08, 2000
					I-197	APR 17, 2000
					I-198	JUN 17, 2000
					I-195	JUN 17, 2000
					I-196	MAY 08, 2000
					I-197	APR 17, 2000
					I-198	JUN 17, 2000
					NCE	JUL 25, 2002

>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020580 001	LIPASE;COTAZYM	5476663	APR 17, 2007		NP	DEC 09, 1999
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5480656	JAN 02, 2013		NC	JUN 26, 2000
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5575987	NOV 19, 2013			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5643607	JUL 01, 2014			
		5489436	FEB 06, 2013			
		5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
		4659716	APR 21, 2004	U-142		
020641 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
018140 001	LORAZEPAM;ATIVAN	5338732	AUG 16, 2011		I-205	SEP 05, 2000
018140 002	LORAZEPAM;ATIVAN				I-205	SEP 05, 2000
020264 001	MEGESTROL ACETATE;MEGACE				I-203	AUG 18, 2000
019651 001	MESALAMINE;ASACOL				NCE	MAR 03, 2000
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NP	SEP 26, 2000
020743 001	METRONIDAZOLE;NORITATE				NCE	JUN 20, 2002
020689 001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
020762 001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
020353 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX				NDF	OCT 01, 2000
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
019660 001	NEDOCROMIL SODIUM;TILADE	5637320	JUN 10, 2014			
020750 001	NEDOCROMIL SODIUM;TILADE					
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		I-183	MAR 06, 2000
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NDF	OCT 01, 2000
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011		NCE	MAR 14, 2002
020381 001	NIACIN;NIASPAN			U-167	NCE	MAR 14, 2002
020381 002	NIACIN;NIASPAN				NCE	JUN 21, 2001
020381 003	NIACIN;NIASPAN				NDF	JUL 28, 2000
020381 004	NIACIN;NIASPAN				NDF	JUL 28, 2000
020381 005	NIACIN;NIASPAN				NDF	JUL 28, 2000
020714 001	NIACIN;NIASPAN TITRATION STARTER PAC				NDF	JUL 28, 2000
020592 001	NICOTINE;NICOTROL				NDF	JUL 28, 2000
020592 002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176	NP	MAY 02, 2000
020592 003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
020592 004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
020592 005	OLANZAPINE;ZYPREXA	4871865	OCT 03, 2006			
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	4923892	MAY 08, 2007	U-174		
		5116863	MAY 26, 2009			
		5641805	JUN 24, 2014	U-184		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019810 001	OMEPRazole; PRILOSEC	4636499 5093342 5599794 5629305 4636499 5093342 5599794 5629305 4753789 4695578 5578628	MAY 30, 2005 FEB 02, 2010 FEB 04, 2014 FEB 04, 2014 MAY 30, 2005 FEB 02, 2010 FEB 04, 2014 FEB 04, 2014 JUN 24, 2006 JUN 25, 2005 JUN 24, 2006	U-166 U-166 U-188		
019810 003	OMEPRazole; PRILOSEC			U-166 U-166 U-188		
020605 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789 4695578 5578628	JUN 24, 2006 JUN 25, 2005 JUN 24, 2006	U-44 U-183 U-44		
019828 001	OXITOMAZOLE NITRATE; OXISTAT	5641803	AUG 03, 2012	U-198	I-200	AUG 18, 2000
020262 001	PACLIITAXEL; TAXOL	5670537 5496804	AUG 03, 2012 MAR 09, 2013	U-198 U-204	OOE I-202	AUG 04, 2004 AUG 04, 2000
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020710 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
019385 001	PERGOLIDE MESYLATE; PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20	NCE	DEC 29, 1997
019385 002	PERGOLIDE MESYLATE; PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20		
019385 003	PERGOLIDE MESYLATE; PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20		
018796 001	PILOCARPINE HYDROCHLORIDE; PILOPINE HS	4271143	MAY 09, 1999		NDF	MAR 13, 2000
020529 001	PODOFILLOX; CONDYLLOX	4680399 5057616	JUL 14, 2004 OCT 15, 2008			
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
019568 001	PREDNICARBATE; DERMATOP	4242334	AUG 02, 2000	U-50		
020279 001	PREDNICARBATE; DERMATOP	4242334	AUG 02, 2000	U-50		
020545 001	PROCAINAMIDE HYDROCHLORIDE; PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE; PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE; CRINONE	4615697 5543150 4615697	OCT 07, 2003 SEP 15, 2013 OCT 07, 2003	U-208 U-209 U-208	NP	JUL 31, 2000
020701 002	PROGESTERONE; CRINONE	5543150	SEP 15, 2013	U-209	NP	JUL 31, 2000
020756 001	PROGESTERONE; CRINONE				NP	MAY 13, 2000
019627 002	PROPOFOL; DIPRIVAN	5543150	SEP 15, 2013		NP	JUN 11, 1999

>ADD>
>ADD>
>ADD>
>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020168 001	SOMATROPIN, BIOSYNTHETIC; NUTROPIN	4816470	DEC 28, 2006		1-182	DEC 30, 1999
020168 002	SOMATROPIN, BIOSYNTHETIC; NUTROPIN	4816470	DEC 28, 2006		00E	DEC 30, 2003
020604 003	SOMATROPIN, BIOSYNTHETIC; SEROSTIM	4816470	DEC 28, 2006		00E	DEC 30, 2003
020626 001	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006		1-182	DEC 30, 1999
020626 002	SUMATRIPTAN; IMITREX	4868216	SEP 19, 2006		NP	AUG 23, 1999
020626 003	SUMATRIPTAN; IMITREX	4731478	OCT 27, 2004		NDF	AUG 26, 2000
020579 001	TAMSULOSIN HYDROCHLORIDE; FLOMAX	4703063	OCT 27, 2004	U-72	NDF	AUG 26, 2000
		4772475	FEB 27, 2006	U-72	NDF	AUG 26, 2000
		5089509	FEB 18, 2009	U-181	NCE	APR 15, 2002
		5089509	FEB 18, 2009			
020600 001	TAZAROTENE; TAZORAC	5045302	AUG 14, 2008			
020600 002	TAZAROTENE; TAZORAC	5504207	APR 29, 2013	U-193	NCE	JUN 13, 2002
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT; MIRALUMA	5294615	APR 29, 2013	U-193	NCE	JUN 13, 2002
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVUE				1-190	MAY 23, 2000
019057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-165		
019057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5294615	APR 29, 2013	U-3		
019057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-165		
019057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5294615	APR 29, 2013	U-3		
020347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-165		
020347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5294615	APR 29, 2013	U-3		
020347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-165		
020347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5294615	APR 29, 2013	U-3		
020192 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	DEC 30, 2006	U-73	1-180	JAN 21, 2000
020192 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73		
020539 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	DEC 30, 2006	U-73		
020539 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73		
020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	5010090	DEC 30, 2006		NDF	OCT 17, 2000
020646 001	TIAGABINE HYDROCHLORIDE; GABITRIL	5354760	OCT 07, 2008		NCE	SEP 30, 2002
020646 002	TIAGABINE HYDROCHLORIDE; GABITRIL	5010090	MAR 24, 2012		NCE	SEP 30, 2002
020646 003	TIAGABINE HYDROCHLORIDE; GABITRIL	5354760	MAR 24, 2012		NCE	SEP 30, 2002
020646 004	TIAGABINE HYDROCHLORIDE; GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012		NCE	SEP 30, 2002

>ADD>
>DLT>
>ADD>
>DLT>
>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	5399578	MAR 21, 2012	U-3	1-207	SEP 26, 2000
020665 001	VALSARTAN; DIOVAN	5399578	MAR 21, 2012	U-3		
020665 002	VALSARTAN; DIOVAN	4535186	DEC 13, 2002		NCE	DEC 28, 1998
020699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4535186	DEC 13, 2002		NDF	OCT 20, 2000
020699 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
020699 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4535186	DEC 13, 2002		NDF	OCT 20, 2000
020699 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
020547 001	ZAFIRLUKAST; ACCOLATE	5612367	MAR 18, 2014	U-189	NDF	OCT 20, 2000
020471 001	ZILEUTON; ZYFLO	5583152	AUG 22, 2006			
020471 003	ZILEUTON; ZYFLO	4873259	FEB 10, 2007	U-168		
020458 001	ZINC ACETATE; GALZIN	4873259	FEB 10, 2007	U-168		
020458 002	ZINC ACETATE; GALZIN				NP	JAN 28, 2000
					ODE	JAN 28, 2004
					NP	JAN 28, 2000
					ODE	JAN 28, 2004

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS



Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

RM301.45 .A66 1997 Oct Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL
ST. LOUIS, MO. 63110

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90036 5681